Valproic	B
acid	I
:	O
decreases	O
oral	O
clearance	O
of	O
temozolomide	B-O
.	O

Administration	O
of	O
valproic	B
acid	I
decreases	O
oral	O
clearance	O
of	O
temozolomide	B-O
by	O
about	O
5	O
%	O
.	O

Food	B
reduces	O
the	O
rate	O
and	O
extent	O
of	O
temozolomide	B-O
absorption	O
.	O

Mean	O
peak	O
plasma	O
concentration	O
and	O
AUC	O
decreased	O
by	O
32	O
%	O
and	O
9	O
%	O
,	O
respectively	O
,	O
and	O
median	O
Tmax	O
increased	O
by	O
2-fold	O
(	O
from	O
1-2.25	O
hours	O
)	O
when	O
temozolomide	B-O
was	O
administered	O
after	O
a	O
modified	O
high-fat	B
breakfast	I
.	O

A	O
population	O
analysis	O
indicated	O
that	O
administration	O
of	O
valproic	B
acid	I
decreases	O
the	O
clearance	O
of	O
temozolomide	B-O
by	O
about	O
5	O
%	O
.	O

Drug	O
Interactions	O
:	O
In	O
a	O
single	O
patient-report	O
,	O
there	O
is	O
the	O
suggestion	O
that	O
concurrent	O
administration	O
of	O
RIDAURA	B
and	O
phenytoin	B-O
may	O
have	O
increased	O
phenytoin	B-O
blood	O
levels	O
.	O

In	O
a	O
drug	O
interaction	O
trial	O
in	O
20	O
healthy	O
subjects	O
,	O
coadministration	O
of	O
inhaled	O
salmeterol	B-O
(	O
50	O
mcg	O
twice	O
daily	O
)	O
and	O
oral	O
ketoconazole	B
(	O
400	O
mg	O
once	O
daily	O
)	O
for	O
7	O
days	O
resulted	O
in	O
greater	O
systemic	O
exposure	O
to	O
salmeterol	B-O
(	O
AUC	O
increased	O
16-fold	O
and	O
Cmax	O
increased	O
1.4-fold	O
)	O
.	O

Drug	O
Interaction	O
Studies	O
Inhibitors	O
of	O
Cytochrome	O
P450	O
3A4	O
:	O
Ketoconazole	B
:	O
In	O
a	O
placebo-controlled	O
crossover	O
drug	O
interaction	O
trial	O
in	O
20	O
healthy	O
male	O
and	O
female	O
subjects	O
,	O
coadministration	O
of	O
salmeterol	B-O
(	O
50	O
mcg	O
twice	O
daily	O
)	O
and	O
the	O
strong	O
CYP3A4	O
inhibitor	O
ketoconazole	B
(	O
400	O
mg	O
once	O
daily	O
)	O
for	O
7	O
days	O
resulted	O
in	O
a	O
significant	O
increase	O
in	O
plasma	O
salmeterol	B-O
exposure	O
as	O
determined	O
by	O
a	O
16-fold	O
increase	O
in	O
AUC	O
(	O
ratio	O
with	O
and	O
without	O
ketoconazole	B
15.76	O
[90	O
%	O
CI	O
:	O
10.66	O
,	O
23.31]	O
)	O
mainly	O
due	O
to	O
increased	O
bioavailability	O
of	O
the	O
swallowed	O
portion	O
of	O
the	O
dose	O
.	O

Erythromycin	B
:	O
In	O
a	O
repeat-dose	O
trial	O
in	O
13	O
healthy	O
subjects	O
,	O
concomitant	O
administration	O
of	O
erythromycin	B
(	O
a	O
moderate	O
CYP3A4	O
inhibitor	O
)	O
and	O
salmeterol	B-O
inhalation	O
aerosol	O
resulted	O
in	O
a	O
40	O
%	O
increase	O
in	O
salmeterol	B-O
Cmax	O
at	O
steady	O
state	O
(	O
ratio	O
with	O
and	O
without	O
erythromycin	B
1.4	O
[90	O
%	O
CI	O
:	O
0.96	O
,	O
2.03]	O
,	O
P	O
=	O
0.12	O
)	O
,	O
a	O
3.6-beat/min	O
increase	O
in	O
heart	O
rate	O
(	O
[95	O
%	O
CI	O
:	O
0.19	O
,	O
7.03]	O
,	O
P<0.04	O
)	O
,	O
a	O
5.8-msec	O
increase	O
in	O
QTc	O
interval	O
(	O
[95	O
%	O
CI	O
:	O
-6.14	O
,	O
17.77]	O
,	O
P	O
=	O
0.34)	O
,	O
and	O
no	O
change	O
in	O
plasma	O
potassium	O
.	O

After	O
oral	O
administration	O
of	O
ketoconazole	B
,	O
a	O
strong	O
inhibitor	O
of	O
CYP3A4	O
,	O
the	O
mean	O
plasma	O
concentration	O
of	O
orally	O
inhaled	O
mometasone	B-O
furoate	I-O
increased	O
.	O

Concomitant	O
administration	O
of	O
CYP3A4	B
inhibitors	I
may	O
inhibit	O
the	O
metabolism	O
of	O
,	O
and	O
increase	O
the	O
systemic	O
exposure	O
to	O
,	O
mometasone	B-O
furoate	I-O
and	O
potentially	O
increase	O
the	O
risk	O
for	O
systemic	O
corticosteroid	O
side	O
effects	O
.	O

Caution	O
should	O
be	O
exercised	O
when	O
considering	O
the	O
coadministration	O
of	O
ASMANEX	B-O
HFA	I-O
with	O
ketoconazole	B
,	O
and	O
other	O
known	O
strong	O
cytochrome	O
P450	B
(	I
CYP	I
)	I
isoenzyme	I
3A4	I
(	I
CYP3A4	I
)	I
inhibitors	I
(	O
e	O
.g.	O
,	O
ritonavir	B
,	O
cobicistat-containing	B
products	I
,	O
atazanavir	B
,	O
clarithromycin	B
,	O
indinavir	B
,	O
itraconazole	B
,	O
nefazodone	B
,	O
nelfinavir	B
,	O
saquinavir	B
,	O
telithromycin	B
)	O
because	O
adverse	O
effects	O
related	O
to	O
increased	O
systemic	O
exposure	O
to	O
mometasone	B-O
furoate	I-O
may	O
occur	O
.	O

Mometasone	B-O
furoate	I-O
plasma	O
levels	O
appeared	O
to	O
increase	O
and	O
plasma	O
cortisol	B-O
levels	O
appeared	O
to	O
decrease	O
upon	O
concomitant	O
administration	O
of	O
ketoconazole	B
.	O

Griseofulvin	B
decreases	O
the	O
activity	O
of	O
warfarin-type	B-O
anticoagulants	I-O
so	O
that	O
patients	O
receiving	O
these	O
drugs	O
concomitantly	O
may	O
require	O
dosage	O
adjustment	O
of	O
the	O
anticoagulant	O
during	O
and	O
after	O
griseofulvin	B
therapy	O
.	O

Barbiturates	B
usually	O
depress	O
griseofulvin	B-O
activity	O
and	O
concomitant	O
administration	O
may	O
require	O
a	O
dosage	O
adjustment	O
of	O
the	O
antifungal	O
agent	O
.	O

Effect	O
of	O
Food	O
:	O
In	O
healthy	O
subjects	O
,	O
a	O
high-fat	B
meal	I
(	O
containing	O
approximately	O
1000	O
calories	O
and	O
55	O
grams	O
of	O
fat	O
)	O
reduced	O
systemic	O
exposure	O
to	O
AFINITOR	B-O
10	O
mg	O
(	O
as	O
measured	O
by	O
AUC)	O
by	O
22	O
%	O
and	O
the	O
peak	O
blood	O
concentration	O
Cmax	O
by	O
54	O
%	O
.	O

In	O
healthy	O
subjects	O
who	O
received	O
9	O
mg	O
of	O
AFINITOR	B-O
DISPERZ	I-O
,	O
high-fat	B
meals	I
(	O
containing	O
approximately	O
1000	O
calories	O
and	O
55	O
grams	O
of	O
fat	O
)	O
reduced	O
everolimus	B-O
AUC	O
by	O
12	O
%	O
and	O
Cmax	O
by	O
60	O
%	O
and	O
low-fat	B
meals	I
(	O
containing	O
approximately	O
500	O
calories	O
and	O
20	O
grams	O
of	O
fat	O
)	O
reduced	O
everolimus	B-O
AUC	O
by	O
30	O
%	O
and	O
Cmax	O
by	O
50	O
%	O
.	O

Drug	O
Interaction	O
Studies	O
Effect	O
of	O
CYP3A4	O
and	O
P-glycoprotein	O
(P-gp	O
)	O
Inhibitors	O
on	O
Everolimus	B-O
:	O
Everolimus	B-O
exposure	O
increased	O
when	O
AFINITOR	B-O
was	O
coadministered	O
with	O
:	O
ketoconazole	B
(	O
a	O
P-gp	O
and	O
strong	O
CYP3A4	O
inhibitor	O
)	O
-	O
Cmax	O
and	O
AUC	O
increased	O
by	O
3.9-	O
and	O
15-fold	O
,	O
respectively	O
.	O
erythromycin	B
(	O
a	O
P-gp	O
and	O
moderate	O
CYP3A4	O
inhibitor	O
)	O
-	O
Cmax	O
and	O
AUC	O
increased	O
by	O
2-	O
and	O
4.4-fold	O
,	O
respectively	O
.	O
verapamil	B
(	O
a	O
P-gp	O
and	O
moderate	O
CYP3A4	O
inhibitor	O
)	O
-	O
Cmax	O
and	O
AUC	O
increased	O
by	O
2.3-	O
and	O
3.5-fold	O
,	O
respectively	O
.	O

Effect	O
of	O
CYP3A4	O
and	O
P-gp	O
Inducers	O
on	O
Everolimus	B-O
:	O
The	O
coadministration	O
of	O
AFINITOR	B-O
with	O
rifampin	B
,	O
a	O
P-gp	O
and	O
strong	O
inducer	O
of	O
CYP3A4	O
,	O
decreased	O
everolimus	B-O
AUC	O
by	O
63	O
%	O
and	O
Cmax	O
by	O
58	O
%	O
compared	O
to	O
AFINITOR	B-O
alone	O
.	O

The	O
coadministration	O
of	O
an	O
oral	O
dose	O
of	O
midazolam	B-O
(	O
sensitive	O
CYP3A4	O
substrate	O
)	O
with	O
AFINITOR	B
resulted	O
in	O
a	O
25	O
%	O
increase	O
in	O
midazolam	B-O
Cmax	O
and	O
a	O
30	O
%	O
increase	O
in	O
midazolam	B-O
AUC0-inf	O
.	O

The	O
coadministration	O
of	O
AFINITOR	B
with	O
exemestane	B-O
increased	O
exemestane	B-O
Cmin	O
by	O
45	O
%	O
and	O
C2h	O
by	O
64	O
%	O
;	O
however	O
,	O
the	O
corresponding	O
estradiol	O
levels	O
at	O
steady	O
state	O
(	O
4	O
weeks	O
)	O
were	O
not	O
different	O
between	O
the	O
2	O
treatment	O
arms	O
.	O

The	O
coadministration	O
of	O
AFINITOR	B
with	O
long	O
acting	O
octreotide	B-O
increased	O
octreotide	B-O
Cmin	O
by	O
approximately	O
50	O
%	O
.	O

Effect	O
of	O
Everolimus	B
on	O
Antiepileptic	O
drugs	O
(	O
AEDs	O
)	O
:	O
Everolimus	B
increased	O
pre-dose	O
concentrations	O
of	O
the	O
carbamazepine	B-O
,	O
clobazam	B-O
,	O
oxcarbazepine	B-O
,	O
and	O
clobazam	B-O
's	O
metabolite	O
N-desmethylclobazam	B-O
by	O
about	O
10	O
%	O
.	O

Inhibitors	B
of	I
CYP3A4	I
activity	O
(	O
such	O
as	O
ketoconazole	B
,	O
itraconazole	B
,	O
ritonavir	B
,	O
indinavir	B
,	O
saquinavir	B
,	O
erythromycin	B
,	O
cyclosporine	B
and	O
grapefruit	B
juice	I
)	O
can	O
increase	O
systemic	O
budesonide	B-O
concentrations	O
.	O

Potent	O
inhibitors	B
of	I
CYP3A4	I
can	O
increase	O
the	O
plasma	O
concentrations	O
of	O
budesonide	B-O
.	O

Co-administration	O
of	O
ketoconazole	B
(	O
inhibitor	O
of	O
CYP3A4	O
)	O
results	O
in	O
an	O
8-fold	O
increase	O
in	O
AUC	O
of	O
oral	O
budesonide	B-O
,	O
compared	O
to	O
budesonide	B-O
alone	O
.	O

Grapefruit	B
juice	I
,	O
an	O
inhibitor	O
of	O
gut	O
mucosal	O
CYP3A	O
,	O
approximately	O
doubles	O
the	O
systemic	O
exposure	O
of	O
oral	O
budesonide	B-O
.	O

Inducers	B
of	I
CYP3A4	I
,	O
such	O
as	O
St	B
.	I
John	I
's	I
Wort	I
(	O
Hypericum	B
perforatum	I
)	O
preparations	O
,	O
phenobarbital	B
,	O
carbamazepine	B
,	O
and	O
rifampin	B
,	O
may	O
reduce	O
plasma	O
concentrations	O
of	O
estrogens	B-O
,	O
possibly	O
resulting	O
in	O
a	O
decrease	O
in	O
therapeutic	O
effects	O
and/or	O
changes	O
in	O
the	O
uterine	O
bleeding	O
profile	O
.	O

Inhibitors	B
of	I
CYP3A4	I
,	O
such	O
as	O
erythromycin	B
,	O
clarithromycin	B
,	O
ketoconazole	B
,	O
itraconazole	B
,	O
ritonavir	B
and	O
grapefruit	B
juice	I
,	O
may	O
increase	O
plasma	O
concentrations	O
of	O
estrogens	B-O
and	O
may	O
result	O
in	O
side	O
effects	O
.	O

PRECOSE	B
may	O
affect	O
digoxin	B-O
bioavailability	O
and	O
may	O
require	O
dose	O
adjustment	O
of	O
digoxin	B-O
by	O
16	O
%	O
(90	O
%	O
confidence	O
interval	O
:	O
8-23	O
%	O
)	O
,	O
decrease	O
mean	O
Cmax	O
of	O
digoxin	B-O
by	O
26	O
%	O
(90	O
%	O
confidence	O
interval	O
:	O
16-34	O
%	O
)	O
and	O
decreases	O
mean	O
trough	O
concentrations	O
of	O
digoxin	B-O
by	O
9	O
%	O
(90	O
%	O
confidence	O
limit	O
:	O
19	O
%	O
decrease	O
to	O
2	O
%	O
increase	O
)	O
.	O

However	O
,	O
the	O
peak	O
plasma	O
level	O
of	O
metformin	B-O
was	O
reduced	O
by	O
approximately	O
20	O
%	O
when	O
taking	O
PRECOSE	B
due	O
to	O
a	O
slight	O
delay	O
in	O
the	O
absorption	O
of	O
metformin	B-O
.	O

Drug	O
Interaction	O
Studies	O
Coadministration	O
of	O
quinine	B
or	O
quinidine	B
with	O
amantadine	B-O
was	O
shown	O
to	O
reduce	O
the	O
renal	O
clearance	O
of	O
amantadine	B-O
by	O
about	O
30	O
%	O
.	O

However	O
,	O
a	O
high	B
fat	I
meal	I
increased	O
systemic	O
exposure	O
of	O
mesalamine	B-O
(	O
mean	O
Cmax	O
:	O
91	O
%	O
;	O
mean	O
AUC	O
:	O
16	O
%	O
)	O
compared	O
to	O
results	O
in	O
the	O
fasted	O
state	O
.	O

There	O
was	O
an	O
increase	O
of	O
12	O
%	O
in	O
Cmax	O
and	O
an	O
increase	O
of	O
15	O
%	O
in	O
AUC	O
of	O
sulfamethoxazole	B-O
when	I-O
sulfamethoxazole/trimethoprim	B-O
was	O
coadministered	O
with	O
LIALDA.	O

There	O
was	O
an	O
increase	O
of	O
12	O
%	O
in	O
Cmax	O
and	O
an	O
increase	O
of	O
15	O
%	O
in	O
AUC	O
of	O
sulfamethoxazole	O
when	O
sulfamethoxazole	O
was	O
coadministered	O
with	I
LIALDA.	B

Teriflunomide	B
may	O
increase	O
exposure	O
of	O
ethinylestradiol	B-O
and	O
levonorgestrel	B-O
.	O

Drugs	B-O
metabolized	I-O
by	I-O
CYP1A2	I-O
:	O
Monitor	O
patients	O
because	O
teriflunomide	B
may	O
decrease	O
exposure	O
of	O
these	O
drugs	O
.	O

Concomitant	O
use	O
of	O
ARAVA	B-O
and	O
rifampin	B
,	O
a	O
potent	O
inducer	O
of	O
CYP	O
and	O
transporters	O
,	O
increased	O
the	O
plasma	O
concentration	O
of	O
teriflunomide	B-O
by	O
40	O
%	O
.	O

Because	O
of	O
the	O
potential	O
for	O
ARAVA	B-O
concentrations	O
to	O
continue	O
to	O
increase	O
with	O
multiple	O
dosing	O
,	O
caution	O
should	O
be	O
used	O
if	O
patients	O
are	O
to	O
be	O
receiving	O
both	O
ARAVA	B-O
and	O
rifampin	B
.	O

In	O
patients	O
taking	O
ARAVA	B
,	O
exposure	O
of	O
drugs	B-O
metabolized	I-O
by	I-O
CYP2C8	I-O
(	O
e	O
.g.	O
,	O
paclitaxel	B-O
,	O
pioglitazone	B-O
,	O
repaglinide	B-O
,	O
rosiglitazone	B-O
)	O
may	O
be	O
increased	O
.	O

Effect	O
on	O
oral	O
contraceptives	O
Teriflunomide	B
may	O
increase	O
the	O
systemic	O
exposures	O
of	O
ethinylestradiol	B-O
and	O
levonorgestrel	B-O
.	O

In	O
patients	O
taking	O
ARAVA	B
,	O
exposure	O
of	O
drugs	B-O
metabolized	I-O
by	I-O
CYP1A2	I-O
(	O
e	O
.g.	O
,	O
alosetron	B-O
,	O
duloxetine	B-O
,	O
theophylline	B-O
,	O
tizanidine	B-O
)	O
may	O
be	O
reduced	O
.	O

In	O
patients	O
taking	O
ARAVA	B
,	O
exposure	O
of	O
drugs	O
which	O
are	O
OAT3	B-O
substrates	I-O
(	O
e	O
.g.	O
,	O
cefaclor	B-O
,	O
cimetidine	B-O
,	O
ciprofloxacin	B-O
,	O
penicillin	B-O
G	I-O
,	O
ketoprofen	B-O
,	O
furosemide	B-O
,	O
methotrexate	B-O
,	O
zidovudine	B-O
)	O
may	O
be	O
increased	O
.	O

For	O
other	O
substrates	B-O
of	I-O
BCRP	I-O
(	O
e	O
.g.	O
,	O
mitoxantrone	B-O
)	O
and	O
drugs	O
in	O
the	O
OATP	B-O
family	I-O
(	O
e	O
.g.	O
,	O
methotrexate	B-O
,	O
rifampin	B-O
)	O
,	O
especially	O
HMG-Co	B-O
reductase	I-O
inhibitors	I-O
(	O
e	O
.g.	O
,	O
atorvastatin	B-O
,	O
nateglinide	B-O
,	O
pravastatin	B-O
,	O
repaglinide	B-O
,	O
and	O
simvastatin	B-O
)	O
,	O
consider	O
reducing	O
the	O
dose	O
of	O
these	O
drugs	O
and	O
monitor	O
patients	O
closely	O
for	O
signs	O
and	O
symptoms	O
of	O
increased	O
exposures	O
to	O
the	O
drugs	O
while	O
patients	O
are	O
taking	O
ARAVA	B
.	O

The	O
elimination	O
of	O
teriflunomide	B-O
can	O
be	O
accelerated	O
by	O
administration	O
of	O
cholestyramine	B
or	O
activated	B
charcoal	I
.	O

The	O
Potential	O
Effect	O
of	O
Other	O
Drugs	O
on	O
ARAVA	B-O
Potent	O
CYP	O
and	O
transporter	O
inducers	O
:	O
Following	O
concomitant	O
administration	O
of	O
a	O
single	O
dose	O
of	O
ARAVA	B-O
to	O
subjects	O
receiving	O
multiple	O
doses	O
of	O
rifampin	B
,	O
teriflunomide	B-O
peak	O
concentrations	O
were	O
increased	O
(	O
~40	O
%	O
)	O
over	O
those	O
seen	O
when	O
ARAVA	B-O
was	O
given	O
alone	O
.	O

The	O
Potential	O
Effect	O
of	O
ARAVA	B
on	O
Other	O
Drugs	O
CYP2C8	O
Substrates	O
There	O
was	O
an	O
increase	O
in	O
mean	O
repaglinide	B-O
Cmax	O
and	O
AUC	O
(	O
1.7-	O
and	O
2.4-fold	O
,	O
respectively	O
)	O
,	O
following	O
repeated	O
doses	O
of	O
teriflunomide	B
and	O
a	O
single	O
dose	O
of	O
0.25	O
mg	O
repaglinide	B-O
,	O
suggesting	O
that	O
teriflunomide	B
is	O
an	O
inhibitor	O
of	O
CYP2C8	O
in	O
vivo	O
.	O

CYP1A2	O
Substrates	O
Repeated	O
doses	O
of	O
teriflunomide	B
decreased	O
mean	O
Cmax	O
and	O
AUC	O
of	O
caffeine	B-O
by	O
18	O
%	O
and	O
55	O
%	O
,	O
respectively	O
,	O
suggesting	O
that	O
teriflunomide	B
may	O
be	O
a	O
weak	O
inducer	O
of	O
CYP1A2	O
in	O
vivo	O
.	O

OAT3	O
Substrates	O
There	O
was	O
an	O
increase	O
in	O
mean	O
cefaclor	B-O
Cmax	O
and	O
AUC	O
(	O
1.43-	O
and	O
1.54-fold	O
,	O
respectively	O
)	O
,	O
following	O
repeated	O
doses	O
of	O
teriflunomide	B
,	O
suggesting	O
that	O
teriflunomide	B
is	O
an	O
inhibitor	O
of	O
organic	O
anion	O
transporter	O
3	O
(	O
OAT3	O
)	O
in	O
vivo	O
.	O

BCRP	O
and	O
OATP1B1/1B3	O
Substrates	O
There	O
was	O
an	O
increase	O
in	O
mean	O
rosuvastatin	B-O
Cmax	O
and	O
AUC	O
(	O
2.65-	O
and	O
2.51-fold	O
,	O
respectively	O
)	O
,	O
following	O
repeated	O
doses	O
of	O
teriflunomide	B
,	O
suggesting	O
that	O
teriflunomide	B
is	O
an	O
inhibitor	O
of	O
BCRP	O
transporter	O
and	O
organic	O
anion	O
transporting	O
polypeptide	O
1B1	O
and	O
1B3	O
(	O
OATP1B1/1B3	O
)	O
.	O

Oral	O
Contraceptives	O
There	O
was	O
an	O
increase	O
in	O
mean	O
ethinylestradiol	B-O
Cmax	O
and	O
AUC0-24	O
(	O
1.58-	O
and	O
1.54-fold	O
,	O
respectively	O
)	O
and	O
levonorgestrel	B-O
Cmax	O
and	O
AUC0-24	O
(	O
1.33-	O
and	O
1.41-fold	O
,	O
respectively	O
)	O
following	O
repeated	O
doses	O
of	O
teriflunomide	B
.	O

Tenofovir	B
disoproxil	I
fumarate	I
increases	O
didanosine	B-O
concentrations	O
.	O

Coadministration	O
of	O
VIREAD	B-O
with	O
certain	O
HIV-1	B
protease	I
inhibitors	I
or	O
certain	O
drugs	B
to	I
treat	I
HCV	I
increases	O
tenofovir	B-O
concentrations	O
.	O

In	O
patients	O
receiving	O
VIREAD	B-O
concomitantly	O
with	O
HARVONI	B
and	O
an	O
HIV-1	B
protease	I
inhibitor/ritonavir	B
or	O
an	O
HIV-1	B
protease	I
inhibitor/cobicistat	B
combination	O
,	O
consider	O
an	O
alternative	O
HCV	O
or	O
antiretroviral	O
therapy	O
,	O
as	O
the	O
safety	O
of	O
increased	O
tenofovir	B-O
concentrations	O
in	O
this	O
setting	O
has	O
not	O
been	O
established	O
.	O

Effects	O
of	O
Food	O
on	O
Oral	O
Absorption	O
Administration	O
of	O
VIREAD	B-O
300	O
mg	O
tablets	O
following	O
a	O
high-fat	B
meal	I
(	O
~700	O
to	O
1,000	O
kcal	O
containing	O
40	O
to	O
50	O
%	O
fat	O
)	O
increases	O
the	O
oral	O
bioavailability	O
,	O
with	O
an	O
increase	O
in	O
tenofovir	B-O
AUC0-Infinity	O
of	O
approximately	O
40	O
%	O
and	O
an	O
increase	O
in	O
Cmax	O
of	O
approximately	O
14	O
%	O
.	O

Food	B
delays	O
the	O
time	O
to	O
tenofovir	B-O
Cmax	O
by	O
approximately	O
1	O
hour	O
.	O

Atazanavir	I-O
Atazanavir/	B-O
Ritonavir	B
300/100	O
once	O
daily	O
-	O
In	O
HIV-infected	O
subjects	O
,	O
addition	O
of	O
TDF	B
to	O
atazanavir	B-O
300	O
mg	O
plus	O
ritonavir	B
100	O
mg	O
,	O
resulted	O
in	O
AUC	O
and	O
Cmin	O
values	O
of	O
atazanavir	B-O
that	O
were	O
2.3-	O
and	O
4-fold	O
higher	O
than	O
the	O
respective	O
values	O
observed	O
for	O
atazanavir	B-O
400	O
mg	O
when	O
given	O
alone	O
.	O

Liraglutide	B
lowered	O
ethinylestradiol	B-O
and	O
levonorgestrel	B-O
Cmax	O
by	O
12	O
%	O
and	O
13	O
%	O
,	O
respectively	O
.	O

Liraglutide	B
increased	O
the	O
levonorgestrel	B-O
AUC0-Infinity	O
by	O
18	O
%	O
.	O

Liraglutide	B
delayed	O
Tmax	O
for	O
both	O
ethinylestradiol	B-O
and	O
levonorgestrel	B-O
by	O
1.5	O
h	O
.	O
Digoxin	O
A	O
single	O
dose	O
of	O
digoxin	O
1	O
mg	O
was	O
administered	O
7	O
hours	O
after	O
the	O
dose	O
of	O
liraglutide	B
at	O
steady	O
state	O
.	O

The	O
concomitant	O
administration	O
with	O
liraglutide	B
resulted	O
in	O
a	O
reduction	O
of	O
digoxin	B-O
AUC	O
by	O
16	O
%	O
;	O
Cmax	O
decreased	O
by	O
31	O
%	O
.	O

The	O
co-administration	O
with	O
liraglutide	B
resulted	O
in	O
a	O
reduction	O
of	O
lisinopril	B-O
AUC	O
by	O
15	O
%	O
;	O
Cmax	O
decreased	O
by	O
27	O
%	O
.	O

Lisinopril	B-O
median	O
Tmax	O
was	O
delayed	O
from	O
6	O
h	O
to	O
8	O
h	O
with	O
liraglutide	B
.	O

Atorvastatin	B-O
Cmax	O
was	O
decreased	O
by	O
38	O
%	O
and	O
median	O
Tmax	O
was	O
delayed	O
from	O
1	O
h	O
to	O
3	O
h	O
with	O
liraglutide	B
.	O

Cholestyramine	B
resin	I
and	O
colestipol	B
HCl	I
-	O
may	O
delay	O
or	O
decrease	O
absorption	O
of	O
bendroflumethiazide	B-O
.	O

Lithium	B-O
generally	O
should	O
not	O
be	O
given	O
with	O
diuretics	O
;	O
diuretic	B
agents	I
reduce	O
the	O
renal	O
clearance	O
of	O
lithium	B-O
and	O
add	O
a	O
high	O
risk	O
of	O
lithium	B-O
toxicity	O
.	O

Co-administration	O
with	O
a	O
strong	O
CYP3A4	B
inhibitor	I
may	O
increase	O
serum	O
levels	O
of	O
cinacalcet	B-O
.	O

Cinacalcet	B-O
Cmax	O
and	O
AUC(0-infinite	O
)	O
were	O
increased	O
by	O
82	O
%	O
and	O
68	O
%	O
,	O
respectively	O
,	O
following	O
administration	O
with	O
a	O
high-fat	B
meal	I
compared	O
with	O
fasting	O
in	O
healthy	O
volunteers	O
.	O

The	O
Cmax	O
and	O
AUC(0-infinite	O
)	O
of	O
cinacalcet	B-O
were	O
increased	O
by	O
65	O
%	O
and	O
50	O
%	O
,	O
respectively	O
,	O
when	O
cinacalcet	B-O
was	O
administered	O
with	O
a	O
low-fat	B
meal	I
compared	O
with	O
fasting	O
.	O

Coadministration	O
with	O
CYP3A	B
inhibitors	I
,	O
including	O
protease	B
inhibitors	I
(	O
except	O
tipranavir/ritonavir	O
)	O
and	O
delavirdine	B
,	O
will	O
increase	O
the	O
concentration	O
of	O
SELZENTRY	B-O
.	O

Coadministration	O
with	O
CYP3A	B
inducers	I
,	O
including	O
efavirenz	B
,	O
may	O
decrease	O
the	O
concentration	O
of	O
SELZENTRY	B-O
.	O

Coadministration	O
of	O
maraviroc	B-O
with	O
St	B
.	I
John	I
's	I
wort	I
is	O
expected	O
to	O
substantially	O
decrease	O
maraviroc	B-O
concentrations	O
and	O
may	O
result	O
in	O
suboptimal	O
levels	O
of	O
maraviroc	B-O
and	O
lead	O
to	O
loss	O
of	O
virologic	O
response	O
and	O
possible	O
resistance	O
to	I-O
maraviroc.	B-O

Effect	O
of	O
Food	O
on	O
Oral	O
Absorption	O
:	O
Coadministration	O
of	O
a	O
300-mg	O
tablet	O
with	O
a	O
high-fat	B
breakfast	I
reduced	O
maraviroc	B-O
Cmax	O
and	O
AUC	O
by	O
33	O
%	O
and	O
coadministration	O
of	O
75	O
mg	O
of	O
oral	O
solution	O
with	O
a	O
high-fat	B
breakfast	I
reduced	O
maraviroc	B-O
AUC	O
by	O
73	O
%	O
in	O
healthy	O
adult	O
volunteers	O
.	O

Maraviroc	B-O
concentrations	O
are	O
higher	O
when	O
SELZENTRY	B-O
150	O
mg	O
is	O
administered	O
with	O
a	O
potent	O
CYP3A	B
inhibitor	I
compared	O
with	O
following	O
administration	O
of	O
300	O
mg	O
without	O
a	O
CYP3A	B
inhibitor	I
,	O
so	O
patients	O
with	O
moderate	O
hepatic	O
impairment	O
who	O
receive	O
SELZENTRY	B-O
150	O
mg	O
with	O
a	O
potent	O
CYP3A	B
inhibitor	I
should	O
be	O
monitored	O
closely	O
for	I-O
maraviroc-associated	B-O
adverse	O
events	O
.	O

The	O
CYP3A/P-gp	O
inhibitors	O
ketoconazole	B
,	O
boceprevir	B
,	I
lopinavir/ritonavir	B
,	O
ritonavir	B
,	I
darunavir/ritonavir	B
,	I
saquinavir/ritonavir	B
,	O
and	O
atazanavir	B
plus/minus	O
ritonavir	B
all	O
increased	O
the	O
Cmax	O
and	O
AUC	O
of	O
maraviroc	B-O
(	O
Table	O
14	O
)	O
.	O

The	O
CYP3A	O
and/or	O
P-gp	O
inducers	O
rifampin	B
,	O
etravirine	B
,	O
and	O
efavirenz	B
decreased	O
the	O
Cmax	O
and	O
AUC	O
of	O
maraviroc	B-O
(	O
Table	O
14	O
)	O
.	O

While	O
not	O
studied	O
,	O
potent	O
CYP3A	O
and/or	O
P-gp	O
inducers	O
carbamazepine	B
,	O
phenobarbital	B
,	O
and	O
phenytoin	B
are	O
expected	O
to	O
decrease	O
maraviroc	B-O
concentrations	O
.	O

Coadministration	O
of	O
fosamprenavir	B-O
700	O
mg/ritonavir	B
100	O
mg	O
twice	O
daily	O
and	O
maraviroc	B
300	O
mg	O
twice	O
daily	O
decreased	O
the	O
Cmin	O
and	O
AUC	O
of	O
amprenavir	B-O
by	O
36	O
%	O
and	O
35	O
%	O
,	O
respectively	O
.	O

Maraviroc	B
decreased	O
the	O
Cmin	O
and	O
AUC	O
of	O
raltegravir	B-O
by	O
27	O
%	O
and	O
37	O
%	O
,	O
respectively	O
,	O
which	O
is	O
not	O
clinically	O
significant	O
.	O

Oral	O
contraceptives	O
:	O
Decreased	O
contraceptive	O
efficacy	O
and	O
increased	O
breakthrough	O
bleeding	O
,	O
especially	O
at	O
doses	O
greater	O
than	O
200	O
mg	O
per	O
day	O
(	O
7.1	O
)	O
Phenytoin	B
or	O
carbamazepine	B
:	O
Concomitant	O
administration	O
with	O
topiramate	B-O
decreased	O
plasma	O
concentrations	O
of	O
topiramate	B-O
(	O
7.2	O
)	O
Lithium	O
:	O
Monitor	O
lithium	O
levels	O
when	O
co-administered	O
with	O
high-dose	O
topiramate	B-O
(	O
7.6	O
)	O
The	O
possibility	O
of	O
decreased	O
contraceptive	O
efficacy	O
and	O
increased	O
breakthrough	O
bleeding	O
should	O
be	O
considered	O
in	O
patients	O
taking	O
combination	O
oral	O
contraceptive	O
products	O
with	O
QUDEXY	O
XR	O
.	O

Concomitant	O
administration	O
of	O
phenytoin	B
or	O
carbamazepine	B
with	O
topiramate	B-O
decreased	O
plasma	O
concentrations	O
of	O
topiramate	B-O
.	O

In	O
patients	O
,	O
there	O
was	O
an	O
observed	O
increase	O
in	O
systemic	O
exposure	O
of	O
lithium	B-O
following	O
topiramate	B
doses	O
of	O
up	O
to	O
600	O
mg	O
per	O
day	O
.	O

Compared	O
to	O
the	O
fasted	O
state	O
,	O
high-fat	B
meal	I
had	O
no	O
effect	O
on	O
bioavailability	O
(	O
AUC	O
and	O
Cmax	O
)	O
but	O
delayed	O
the	O
Tmax	O
by	O
approximately	O
4	O
hours	O
following	O
a	O
single	O
dose	O
of	O
QUDEXY	B-O
XR	I-O
.	O

In	O
rats	O
,	O
given	O
probenecid	B
to	O
inhibit	O
tubular	O
reabsorption	O
,	O
along	O
with	O
topiramate	B-O
,	O
a	O
significant	O
increase	O
in	O
renal	O
clearance	O
of	O
topiramate	B-O
was	O
observed	O
.	O

Pediatric	O
patients	O
on	O
adjunctive	O
treatment	O
exhibited	O
a	O
higher	O
oral	O
clearance	O
(	O
L/h	O
)	O
of	O
topiramate	B-O
compared	O
to	O
patients	O
on	O
monotherapy	O
,	O
presumably	O
because	O
of	O
increased	O
clearance	O
from	O
concomitant	O
enzyme-inducing	B
antiepileptic	I
drugs	I
.	O

As	O
in	O
adults	O
,	O
hepatic	B
enzyme-inducing	I
antiepileptic	I
drugs	I
decrease	O
the	O
steady	O
state	O
plasma	O
concentrations	O
of	O
topiramate	B-O
.	O

Digoxin	B-O
In	O
a	O
single-dose	O
study	O
,	O
serum	O
digoxin	B-O
AUC	O
was	O
decreased	O
by	O
12	O
%	O
with	O
concomitant	O
topiramate	B
administration	O
.	O

The	O
results	O
of	O
this	O
study	O
indicate	O
that	O
topiramate	B-O
Cmax	O
increased	O
by	O
27	O
%	O
and	O
AUC	O
increased	O
by	O
29	O
%	O
when	O
HCTZ	B
was	O
added	O
to	O
topiramate	B-O
.	O

The	O
results	O
of	O
this	O
study	O
indicated	O
that	O
the	O
mean	O
metformin	B-O
Cmax	O
and	O
AUC0-12h	O
increased	O
by	O
18	O
%	O
and	O
25	O
%	O
,	O
respectively	O
,	O
when	O
topiramate	B
was	O
added	O
.	O

There	O
was	O
a	O
22	O
%	O
decrease	O
in	O
Cmax	O
and	O
25	O
%	O
reduction	O
in	O
AUC24	O
for	O
glyburide	B-O
during	O
topiramate	B
administration	O
.	O

Lithium	B-O
In	O
patients	O
,	O
the	O
pharmacokinetics	O
of	O
lithium	B-O
were	O
unaffected	O
during	O
treatment	O
with	O
topiramate	B
at	O
doses	O
of	O
200	O
mg	O
per	O
day	O
;	O
however	O
,	O
there	O
was	O
an	O
observed	O
increase	O
in	O
systemic	O
exposure	O
of	O
lithium	B-O
(	O
27	O
%	O
for	O
Cmax	O
and	O
26	O
%	O
for	O
AUC)	O
following	O
topiramate	B
doses	O
up	O
to	O
600	O
mg	O
per	O
day	O
.	O

Amitriptyline	B-O
There	O
was	O
a	O
12	O
%	O
increase	O
in	O
AUC	O
and	O
Cmax	O
for	O
amitriptyline	B-O
(	O
25	O
mg	O
per	O
day	O
)	O
in	O
18	O
normal	O
subjects	O
(	O
9	O
males	O
,	O
9	O
females	O
)	O
receiving	O
200	O
mg	O
per	O
day	O
of	O
topiramate	B
.	O

Some	O
subjects	O
may	O
experience	O
a	O
large	O
increase	O
in	O
amitriptyline	B-O
concentration	O
in	O
the	O
presence	O
of	O
QUDEXY	B
XR	I
and	O
any	O
adjustments	O
in	O
amitriptyline	B-O
dose	O
should	O
be	O
made	O
according	O
to	O
the	O
patient	O
's	O
clinical	O
response	O
and	O
not	O
on	O
the	O
basis	O
of	O
plasma	O
levels	O
.	O

Risperidone	B-O
When	O
administered	O
concomitantly	O
with	O
topiramate	B
at	O
escalating	O
doses	O
of	O
100	O
,	O
250	O
,	O
and	O
400	O
mg	O
per	O
day	O
,	O
there	O
was	O
a	O
reduction	O
in	O
risperidone	B-O
systemic	O
exposure	O
(	O
16	O
%	O
and	O
33	O
%	O
for	O
steady-state	O
AUC	O
at	O
the	O
250	O
and	O
400	O
mg	O
per	O
day	O
doses	O
of	O
topiramate	B
)	O
.	O

Coadministration	O
of	O
topiramate	B-O
400	O
mg	O
per	O
day	O
with	O
risperidone	B
resulted	O
in	O
a	O
14	O
%	O
increase	O
in	O
Cmax	O
and	O
a	O
12	O
%	O
increase	O
in	O
AUC12	O
of	O
topiramate	B-O
.	O

Diltiazem	B-O
Co-administration	O
of	O
diltiazem	B-O
(	O
240	O
mg	O
)	O
with	O
topiramate	B
(	O
150	O
mg	O
per	O
day	O
)	O
resulted	O
in	O
a	O
10	O
%	O
decrease	O
in	O
Cmax	O
and	O
25	O
%	O
decrease	O
in	O
diltiazem	B-O
AUC	O
,	O
27	O
%	O
decrease	O
in	O
Cmax	O
and	O
18	O
%	O
decrease	O
in	O
des-acetyl	B-O
diltiazem	I-O
AUC	O
,	O
and	O
no	O
effect	O
on	O
N-desmethyl	O
diltiazem	B-O
.	O

Co-administration	O
of	O
topiramate	B-O
with	O
diltiazem	B
resulted	O
in	O
a	O
16	O
%	O
increase	O
in	O
Cmax	O
and	O
a	O
19	O
%	O
increase	O
in	O
AUC12	O
of	O
topiramate	B-O
.	O

The	O
benzyl	B
alcohol	I
contained	O
in	O
MESNEX	O
injection	O
vials	O
can	O
reduce	O
the	O
stability	O
of	O
ifosfamide	B-O
.	O

Maximum	O
plasma	O
concentrations	O
of	O
misoprostol	B-O
acid	I-O
are	O
diminished	O
when	O
the	O
dose	O
is	O
taken	O
with	O
food	B
and	O
total	O
availability	O
of	O
misoprostol	B-O
acid	I-O
is	O
reduced	O
by	O
use	O
of	O
concomitant	O
antacid	B
.	O

Drug	O
interaction	O
studies	O
between	O
misoprostol	B
and	O
several	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
showed	O
no	O
effect	O
on	O
the	O
kinetics	O
of	O
ibuprofen	O
or	O
diclofenac	O
,	O
and	O
a	O
20	O
%	O
decrease	O
in	O
aspirin	B-O
AUC	O
,	O
not	O
thought	O
to	O
be	O
clinically	O
significant	O
.	O

Because	O
food	B
can	O
reduce	O
the	O
bioavailability	O
of	O
zafirlukast	B-O
,	O
ACCOLATE	B-O
should	O
be	O
taken	O
at	O
least	O
1	O
hour	O
before	O
or	O
2	O
hours	O
after	O
meals	O
.	O

In	O
a	O
drug	O
interaction	O
study	O
in	O
16	O
healthy	O
male	O
volunteers	O
,	O
coadministration	O
of	O
multiple	O
doses	O
of	O
zafirlukast	B
(	O
160	O
mg/day	O
)	O
to	O
steady-state	O
with	O
a	O
single	O
25	O
mg	O
dose	O
of	O
warfarin	B-O
resulted	O
in	O
a	O
significant	O
increase	O
in	O
the	O
mean	O
AUC	O
(	O
+	O
63	O
%	O
)	O
and	O
half-life	O
(	O
+36	O
%	O
)	O
of	O
S-warfarin	B-O
.	O

In	O
a	O
drug	O
interaction	O
study	O
in	O
11	O
asthmatic	O
patients	O
,	O
coadministration	O
of	O
a	O
single	O
dose	O
of	O
zafirlukast	B-O
(	O
40	O
mg	O
)	O
with	O
erythromycin	B
(	O
500	O
mg	O
three	O
times	O
daily	O
for	O
5	O
days	O
)	O
to	O
steady-state	O
resulted	O
in	O
decreased	O
mean	O
plasma	O
levels	O
of	O
zafirlukast	B-O
by	O
approximately	O
40	O
%	O
due	O
to	O
a	O
decrease	O
in	O
zafirlukast	B-O
bioavailability	O
.	O

Coadministration	O
of	O
zafirlukast	B-O
(	O
80	O
mg/day	O
)	O
at	O
steady-state	O
with	O
a	O
single	O
dose	O
of	O
a	O
liquid	O
theophylline	B
preparation	O
(	O
6	O
mg/kg	O
)	O
in	O
13	O
asthmatic	O
patients	O
,	O
18	O
to	O
44	O
years	O
of	O
age	O
,	O
resulted	O
in	O
decreased	O
mean	O
plasma	O
levels	O
of	O
zafirlukast	B-O
by	O
approximately	O
30	O
%	O
,	O
but	O
no	O
effect	O
on	O
plasma	O
theophylline	B
levels	O
was	O
observed	O
.	O

Rare	O
cases	O
of	O
patients	O
experiencing	O
increased	O
theophylline	B-O
levels	O
with	O
or	O
without	O
clinical	O
signs	O
or	O
symptoms	O
of	O
theophylline	B-O
toxicity	O
after	O
the	O
addition	O
of	O
ACCOLATE	B
to	O
an	O
existing	O
theophylline	B-O
regimen	O
have	O
been	O
reported	O
.	O

Coadministration	O
of	O
zafirlukast	B-O
(	O
40	O
mg/day	O
)	O
with	O
aspirin	B
(	O
650	O
mg	O
four	O
times	O
daily	O
)	O
resulted	O
in	O
mean	O
increased	O
plasma	O
levels	O
of	O
zafirlukast	B-O
by	O
approximately	O
45	O
%	O
.	O

The	O
bioavailability	O
of	O
ACCOLATE	B-O
may	O
be	O
decreased	O
when	O
taken	O
with	O
food	B
.	O

In	O
two	O
separate	O
studies	O
,	O
one	O
using	O
a	O
high	O
fat	O
and	O
the	O
other	O
a	O
high	O
protein	O
meal	O
,	O
administration	O
of	O
zafirlukast	B-O
with	O
food	B
reduced	O
the	O
mean	O
bioavailability	O
by	O
approximately	O
40	O
%	O
.	O

Coadministration	O
of	O
multiple	O
doses	O
of	O
zafirlukast	B
(	O
160	O
mg/day	O
)	O
to	O
steady-state	O
with	O
a	O
single	O
25	O
mg	O
dose	O
of	O
warfarin	B-O
(	O
a	O
substrate	O
of	O
CYP2C9	O
)	O
resulted	O
in	O
a	O
significant	O
increase	O
in	O
the	O
mean	O
AUC	O
(	O
+63	O
%	O
)	O
and	O
half-life	O
(	O
+36	O
%	O
)	O
of	O
S-warfarin	B-O
.	O

Coadministration	O
of	O
a	O
single	O
dose	O
of	O
zafirlukast	B-O
(	O
40	O
mg	O
)	O
with	O
erythromycin	B
(	O
500	O
mg	O
three	O
times	O
daily	O
for	O
5	O
days	O
)	O
to	O
steady-state	O
in	O
11	O
asthmatic	O
patients	O
resulted	O
in	O
decreased	O
mean	O
plasma	O
concentrations	O
of	O
zafirlukast	B-O
by	O
approximately	O
40	O
%	O
due	O
to	O
a	O
decrease	O
in	O
zafirlukast	B-O
bioavailability	O
.	O

Concomitant	O
administration	O
of	O
Sandostatin	B
with	O
cyclosporine	B-O
may	O
decrease	O
blood	O
levels	O
of	O
cyclosporine	B-O
and	O
result	O
in	O
transplant	O
rejection	O
.	O

Concomitant	O
administration	O
of	O
octreotide	B
and	O
bromocriptine	B-O
increases	O
the	O
availability	O
of	O
bromocriptine	B-O
.	O

Depressed	O
vitamin	B-O
B12	I-O
levels	O
and	O
abnormal	O
Schilling	O
's	O
tests	O
have	O
been	O
observed	O
in	O
some	O
patients	O
receiving	O
Sandostatin	B
therapy	O
,	O
and	O
monitoring	O
of	O
vitamin	B-O
B12	I-O
levels	O
is	O
recommended	O
during	O
chronic	O
Sandostatin	B
therapy	O
.	O

Coadministration	O
of	O
the	O
potent	O
CYP3A4	O
inhibitor	O
ketoconazole	B
with	O
fesoterodine	O
led	O
to	O
approximately	O
a	O
doubling	O
of	O
the	O
maximum	O
concentration	O
(	O
Cmax	O
)	O
and	O
area	O
under	O
the	O
concentration	O
versus	O
time	O
curve	O
(	O
AUC)	O
of	O
5-hydroxymethyl	B-O
tolterodine	I-O
(5-HMT	O
)	O
,	O
the	O
active	O
metabolite	O
of	O
fesoterodine	O
.	O

Following	O
blockade	O
of	O
CYP3A4	O
by	O
coadministration	O
of	O
the	O
moderate	O
CYP3A4	O
inhibitor	O
fluconazole	B
200	O
mg	O
twice	O
a	O
day	O
for	O
2	O
days	O
,	O
the	O
average	O
(90	O
%	O
confidence	O
interval	O
)	O
increase	O
in	O
Cmax	O
and	O
AUC	O
of	O
the	O
active	B-O
metabolite	I-O
of	I-O
fesoterodine	I-O
was	O
approximately	O
19	O
%	O
(	O
11	O
%	O
-	O
28	O
%	O
)	O
and	O
27	O
%	O
(	O
18	O
%	O
-	O
36	O
%	O
)	O
respectively	O
.	O

Following	O
induction	O
of	O
CYP3A4	O
by	O
coadministration	O
of	O
rifampin	B
600	O
mg	O
once	O
a	O
day	O
,	O
Cmax	O
and	O
AUC	O
of	O
the	O
active	B-O
metabolite	I-O
of	I-O
fesoterodine	I-O
decreased	O
by	O
approximately	O
70	O
%	O
and	O
75	O
%	O
,	O
respectively	O
,	O
after	O
oral	O
administration	O
of	O
Toviaz	O
8	O
mg	O
.	O

CYP3A4	O
Inducers	O
:	O
Following	O
induction	O
of	O
CYP3A4	O
by	O
coadministration	O
of	O
rifampicin	B
600	O
mg	O
once	O
a	O
day	O
,	O
Cmax	O
and	O
AUC	O
of	O
the	O
active	B-O
metabolite	I-O
of	I-O
fesoterodine	I-O
decreased	O
by	O
approximately	O
70	O
%	O
and	O
75	O
%	O
,	O
respectively	O
,	O
after	O
oral	O
administration	O
of	O
Toviaz	O
8	O
mg	O
.	O

Fesoterodine	B
increased	O
the	O
AUC	O
and	O
Cmax	O
of	O
ethinyl	B-O
estradiol	I-O
by	O
1	O
-	O
3	O
%	O
and	O
decreased	O
the	O
AUC	O
and	O
Cmax	O
of	O
levonorgestrel	B-O
by	O
11	O
-	O
13	O
%	O
.	O

However	O
,	O
peak	O
plasma	O
levels	O
are	O
significantly	O
reduced	O
when	O
STARLIX	B-O
is	O
administered	O
10	O
minutes	O
prior	O
to	O
a	O
liquid	B
meal	I
as	O
compared	O
to	O
solid	O
meal	O
.	O

Drug	O
Interactions	O
:	O
In	O
vitro	O
assessment	O
of	O
drug	O
interactions	O
STARLIX	B
is	O
a	O
potential	O
inhibitor	O
of	O
the	O
CYP2C9	O
isoenzyme	O
in	O
vivo	O
as	O
indicated	O
by	O
its	O
ability	O
to	O
inhibit	O
the	O
in	O
vitro	O
metabolism	O
of	O
tolbutamide	B-O
.	O

Buprenorphine	B-O
is	O
metabolized	O
to	O
norbuprenorphine	B-O
primarily	O
by	O
CYP3A4	O
;	O
therefore	O
,	O
potential	O
interactions	O
may	O
occur	O
when	O
SUBLOCADE	B-O
is	O
given	O
concurrently	O
with	O
agents	O
that	O
affect	O
CYP3A4	O
activity	O
.The	O
concomitant	O
use	O
of	O
sublingual	O
buprenorphine	B-O
and	O
CYP3A4	B
inhibitors	I
(	O
e	O
.g.	O
,	O
ketoconazole	B
)	O
can	O
increase	O
the	O
plasma	O
concentration	O
of	O
buprenorphine	B-O
,	O
resulting	O
in	O
increased	O
or	O
prolonged	O
opioid	O
effects	O
.	O

Other	O
PIs	O
with	O
CYP3A4	O
inhibitory	O
activity	O
(atazanavir	B
and	I
atazanavir/ritonavir	B
)	O
resulted	O
in	O
elevated	O
levels	O
of	O
buprenorphine	B-O
and	O
norbuprenorphine	B-O
after	O
sublingual	O
administration	O
,	O
and	O
patients	O
in	O
one	O
study	O
reported	O
increased	O
sedation	O
.	O

Aminosalicylic	B
acid	I
at	O
a	O
dosage	O
of	O
12	O
grams	O
in	O
a	O
rapidly	O
available	O
form	O
has	O
been	O
reported	O
to	O
produce	O
a	O
20	O
percent	O
reduction	O
in	O
the	O
acetylation	O
of	O
isoniazid	B-O
,	O
especially	O
in	O
patients	O
who	O
are	O
rapid	O
acetylators	O
;	O
INH	O
serum	O
levels	O
,	O
half	O
lives	O
and	O
excretions	O
in	O
fast	O
acetylators	O
still	O
remain	O
half	O
of	O
the	O
levels	O
seen	O
in	O
slow	O
acetylators	O
with	O
or	O
without	O
p-aminosalicylic	B
acid	I
.	O

Aminosalicylic	B
acid	I
has	O
previously	O
been	O
reported	O
to	O
block	O
the	O
absorption	O
of	O
rifampin	B-O
.	O

As	O
a	O
result	O
of	O
competition	O
,	O
Vitamin	B-O
B12	I-O
absorption	O
has	O
been	O
reduced	O
55	O
%	O
by	O
5	O
grams	O
of	O
aminosalicylic	B
acid	I
with	O
clinically	O
significant	O
erythrocyte	O
abnormalities	O
developing	O
after	O
depletion	O
;	O
patients	O
on	O
therapy	O
of	O
more	O
than	O
one	O
month	O
should	O
be	O
considered	O
for	O
maintenance	O
B12	O
.	O

Studies	O
have	O
shown	O
that	O
the	O
bioavailability	O
of	O
isoniazid	B-O
is	O
reduced	O
significantly	O
when	O
administered	O
with	O
food	B
.	O

Isoniazid	B
is	O
known	O
to	O
slow	O
the	O
metabolism	O
of	O
carbamazepine	B-O
and	O
increase	O
its	O
serum	O
levels	O
.	O

When	O
Ketoconazole	B-O
is	O
given	O
in	O
combination	O
with	O
isoniazid	B
and	O
rifampin	B
the	O
AUC	O
of	O
Ketoconazole	B-O
is	O
decreased	O
by	O
as	O
much	O
as	O
88	O
%	O
after	O
5	O
months	O
of	O
concurrent	O
Isoniazid	B
and	O
Rifampin	B
therapy	O
.	O

Isoniazid	B
may	O
increase	O
serum	O
levels	O
of	O
phenytoin	B-O
.	O

A	O
recent	O
case	O
study	O
has	O
shown	O
a	O
possible	O
increase	O
in	O
the	O
plasma	O
level	O
of	O
valproate	B-O
when	O
co-administered	O
with	O
isoniazid	B
.	O

In	O
addition	O
,	O
when	O
administered	O
intravenously	O
,	O
diuretics	B
may	O
enhance	O
neomycin	B-O
toxicity	O
by	O
altering	O
the	O
antibiotic	O
concentration	O
in	O
serum	O
and	O
tissue	O
.	O

Oral	O
neomycin	B
inhibits	O
the	O
gastrointestinal	O
absorption	O
of	O
penicillin	B-O
V	I-O
,	O
oral	B-O
vitamin	I-O
B-12	I-O
,	O
methotrexate	B-O
and	O
5-fluorouracil	B-O
.	O

Oral	O
neomycin	B
sulfate	I
may	O
enhance	O
the	O
effect	O
of	O
coumarin	B-O
in	O
anticoagulants	O
by	O
decreasing	O
vitamin	O
K	O
availability	O
.	O

Food	O
Effects	O
:	O
A	O
high-fat	B
meal	I
decreased	O
the	O
extent	O
and	O
rate	O
of	O
alvimopan	B-O
absorption	O
.	O

Combined	O
hormonal	B
contraceptives	I
have	O
been	O
shown	O
to	O
significantly	O
decrease	O
plasma	O
concentrations	O
of	O
lamotrigine	B-O
when	O
coadministered	O
,	O
likely	O
due	O
to	O
induction	O
of	O
lamotrigine	B-O
glucuronidation	O
.	O

Avoid	O
the	O
use	O
of	O
calcium	B
supplements	O
within	O
60	O
minutes	O
of	O
BONIVA	B-O
administration	O
because	O
co-administration	O
of	O
BONIVA	B-O
and	O
calcium	B
may	O
interfere	O
with	O
the	O
absorption	O
of	O
ibandronate	B-O
sodium	I-O
.	O

Calcium	B
supplements	I
,	O
antacids	B
and	O
some	O
oral	O
medications	O
may	O
interfere	O
with	O
absorption	O
of	O
ibandronate	B-O
.	O

Products	O
containing	O
calcium	B
and	O
other	O
multivalent	B
cations	I
(	O
such	O
as	O
aluminum	B
,	O
magnesium	B
,	O
iron	B
)	O
are	O
likely	O
to	O
interfere	O
with	O
absorption	O
of	O
BONIVA	B-O
.	O

In	O
healthy	O
volunteers	O
,	O
co-administration	O
with	O
ranitidine	B
resulted	O
in	O
a	O
20	O
%	O
increased	O
bioavailability	O
of	O
ibandronate	B-O
,	O
which	O
was	O
not	O
considered	O
to	O
be	O
clinically	O
relevant	O
.	O

The	O
oral	O
bioavailability	O
of	O
ibandronate	B-O
is	O
reduced	O
by	O
about	O
90	O
%	O
when	O
BONIVA	B-O
is	O
administered	O
concomitantly	O
with	O
a	O
standard	O
breakfast	B
in	O
comparison	O
with	O
bioavailability	O
observed	O
in	O
fasted	O
subjects	O
.	O

However	O
,	O
both	O
bioavailability	O
and	O
the	O
effect	O
on	O
bone	O
mineral	O
density	O
(	O
BMD)	O
are	O
reduced	O
when	O
food	B
or	I
beverages	I
are	O
taken	O
less	O
than	O
60	O
minutes	O
following	O
an	O
ibandronate	B-O
dose	O
.	O

Drug	O
Interaction	O
Studies	O
Products	O
containing	O
calcium	B
and	O
other	O
multivalent	B
cations	I
(	O
such	O
as	O
aluminum	B
,	O
magnesium	B
,	O
iron	B
)	O
,	O
including	O
milk	B
,	O
food	B
,	O
and	O
antacids	B
are	O
likely	O
to	O
interfere	O
with	O
absorption	O
of	O
ibandronate	B-O
,	O
which	O
is	O
consistent	O
with	O
findings	O
in	O
animal	O
studies	O
.	O

H2	O
Blockers	O
A	O
pharmacokinetic	O
interaction	O
study	O
in	O
healthy	O
volunteers	O
demonstrated	O
that	O
75	O
mg	O
ranitidine	B
(	O
25	O
mg	O
injected	O
intravenously	O
90	O
and	O
15	O
minutes	O
before	O
and	O
30	O
minutes	O
after	O
ibandronate	B-O
administration	O
)	O
increased	O
the	O
oral	O
bioavailability	O
of	O
10	O
mg	O
ibandronate	B-O
by	O
about	O
20	O
%	O
.	O

Concurrent	O
use	O
of	O
propantheline	B
with	O
slow-dissolving	O
tablets	O
of	O
digoxin	B-O
may	O
cause	O
increased	O
serum	O
digoxin	B-O
levels	O
.	O

Drug	O
Interactions	O
Changes	O
in	O
contraceptive	O
effectiveness	O
associated	O
with	O
coadministration	O
of	O
other	O
products	O
:	O
Contraceptive	O
effectiveness	O
may	O
be	O
reduced	O
when	O
hormonal	B-O
contraceptives	I-O
are	O
coadministered	O
with	O
antibiotics	B
,	O
anticonvulsants	B
,	O
and	O
other	O
drugs	O
that	O
increase	O
the	O
metabolism	O
of	O
contraceptive	O
steroids	O
.	O

Increase	O
in	O
plasma	O
levels	O
associated	O
with	O
coadministered	O
drugs	O
:	O
Coadministration	O
of	O
atorvastatin	B
and	O
certain	O
oral	O
contraceptives	O
containing	O
ethinyl	B-O
estradiol	I-O
increase	O
AUC	O
values	O
for	O
ethinyl	B-O
estradiol	I-O
by	O
approximately	O
20	O
%	O
.	O

Ascorbic	B
acid	I
and	O
acetaminophen	B
may	O
increase	O
plasma	O
ethinyl	B-O
estradiol	I-O
levels	O
,	O
possibly	O
by	O
inhibition	O
of	O
conjugation	O
.	O

Increased	O
plasma	O
concentrations	O
of	O
cyclosporin	B-O
,	O
prednisolone	B-O
and	O
theophylline	B-O
have	O
been	O
reported	O
with	O
concomitant	O
administration	O
of	O
oral	B
contraceptives	I
.	O

Decreased	O
plasma	O
concentrations	O
of	O
acetaminophen	B-O
and	O
increased	O
clearance	O
of	O
temazepam	B-O
,	O
salicylic	B-O
acid	I-O
,	O
morphine	B-O
,	O
and	O
clofibric	B-O
acid	I-O
,	O
due	O
to	O
induction	O
of	O
conjugation	O
,	O
have	O
been	O
noted	O
when	O
these	O
drugs	O
were	O
administered	O
with	O
oral	B
contraceptives	I
.	O

Decreased	O
exposure	O
of	O
some	O
antiretroviral	O
drugs	O
(	O
e	O
.g.	O
,	O
rilpivirine	B-O
,	O
atazanavir	B-O
,	O
and	O
nelfinavir	B-O
)	O
when	O
used	O
concomitantly	O
with	O
dexlansoprazole	B
may	O
reduce	O
antiviral	O
effect	O
and	O
promote	O
the	O
development	O
of	O
drug	O
resistance	O
.	O

Increased	O
exposure	O
of	O
other	O
antiretroviral	B
drugs	I
(	O
e	O
.g.	O
,	O
saquinavir	B
)	O
when	O
used	O
concomitantly	O
with	O
dexlansoprazole	B-O
may	O
increase	O
toxicity	O
of	O
the	O
antiretroviral	B
drugs	I
.	O

Methotrexate	B-O
Clinical	O
Impact	O
:	O
Concomitant	O
use	O
of	O
PPIs	B
with	O
methotrexate	B-O
(	O
primarily	O
at	O
high	O
dose	O
)	O
may	O
elevate	O
and	O
prolong	O
serum	O
concentrations	O
of	O
methotrexate	B-O
and/or	O
its	O
metabolite	O
hydroxymethotrexate	B-O
,	O
possibly	O
leading	O
to	O
methotrexate	B-O
toxicities	O
.	O

Drugs	B-O
Dependent	I-O
on	I-O
Gastric	I-O
pH	I-O
for	I-O
Absorption	I-O
(	O
e	O
.g.	O
,	O
iron	B-O
salts	I-O
,	O
erlotinib	B-O
,	O
dasatinib	B-O
,	O
nilotinib	B-O
,	O
mycophenolate	B-O
mofetil	I-O
,	I-O
ketoconazole/itraconazole	B-O
)	O
Clinical	O
Impact	O
:	O
Dexlansoprazole	B
can	O
reduce	O
the	O
absorption	O
of	O
other	O
drugs	O
due	O
to	O
its	O
effect	O
on	O
reducing	O
intragastric	O
acidity	O
.	O

Intervention	O
:	O
Mycophenolate	B-O
mofetil	I-O
(	O
MMF)	O
:	O
Co-administration	O
of	O
PPIs	B
in	O
healthy	O
subjects	O
and	O
in	O
transplant	O
patients	O
receiving	O
MMF	O
has	O
been	O
reported	O
to	O
reduce	O
the	O
exposure	O
to	O
the	O
active	O
metabolite	O
,	O
mycophenolic	B-O
acid	I-O
(	O
MPA	O
)	O
,	O
possibly	O
due	O
to	O
a	O
decrease	O
in	O
MMF	O
solubility	O
at	O
an	O
increased	O
gastric	O
pH.	O

Clinically	O
Relevant	O
Interactions	O
Affecting	O
DEXILANT	B-O
When	O
Co-Administered	O
with	O
Other	O
Drugs	O
and	O
Substances	O
CYP2C19	B
or	I
CYP3A4	I
Inducers	I
Clinical	O
Impact	O
:	O
Decreased	O
exposure	O
of	O
dexlansoprazole	B-O
when	O
used	O
concomitantly	O
with	O
strong	O
inducers	O
.	O

CYP2C19	B
or	I
CYP3A4	I
Inhibitors	I
Clinical	O
Impact	O
:	O
Increased	O
exposure	O
of	O
dexlansoprazole	B-O
is	O
expected	O
when	O
used	O
concomitantly	O
with	O
strong	O
inhibitors	O
.	O

Interaction	O
with	O
Methotrexate	O
:	O
Concomitant	O
use	O
with	O
PPIs	B
may	O
elevate	O
and/or	O
prolong	O
serum	O
concentrations	O
of	O
methotrexate	B-O
and/or	I-O
its	I-O
metabolite	I-O
,	O
possibly	O
leading	O
to	O
toxicity	O
.	O

Daily	O
treatment	O
with	O
any	O
acid-suppressing	B
medications	I
over	O
a	O
long	O
period	O
of	O
time	O
(	O
e	O
.g.	O
,	O
longer	O
than	O
three	O
years	O
)	O
may	O
lead	O
to	O
malabsorption	O
of	O
cyanocobalamin	B-O
(	O
Vitamin	B-O
B12	I-O
)	O
caused	O
by	O
hypo-	O
or	O
achlorhydria	O
.	O

Rare	O
reports	O
of	O
cyanocobalamin	B-O
deficiency	O
occurring	O
with	O
acid-suppressing	B
therapy	I
have	O
been	O
reported	O
in	O
the	O
literature	O
.	O

Literature	O
suggests	O
that	O
concomitant	O
use	O
of	O
PPIs	B
with	O
methotrexate	O
(	O
primarily	O
at	O
high	O
dose	O
)	O
may	O
elevate	O
and	O
prolong	O
serum	O
levels	B-O
of	I-O
methotrexate	I-O
and/or	I-O
its	I-O
metabolite	I-O
,	O
possibly	O
leading	O
to	O
methotrexate	O
toxicities	O
.	O

Effect	O
on	O
Food	B
In	I
food-effect	B
studies	O
in	O
healthy	O
subjects	O
receiving	O
DEXILANT	B-O
under	O
various	O
fed	O
conditions	O
compared	O
to	O
fasting	O
,	O
increases	O
in	O
Cmax	O
ranged	O
from	O
12	O
to	O
55	O
%	O
,	O
increases	O
in	O
AUC	O
ranged	O
from	O
9	O
to	O
37	O
%	O
,	O
and	O
Tmax	O
varied	O
(	O
ranging	O
from	O
a	O
decrease	O
of	O
0.7	O
hours	O
to	O
an	O
increase	O
of	O
three	O
hours	O
)	O
.	O

Lithium	B-O
generally	O
should	O
not	O
be	O
given	O
with	O
diuretics	B
because	O
they	O
reduce	O
its	O
renal	O
clearance	O
and	O
add	O
a	O
high	O
risk	O
of	O
lithium	B-O
toxicity	O
.	O

A	O
number	O
of	O
drugs	O
,	O
including	O
ethacrynic	B
acid	I
,	O
have	O
been	O
shown	O
to	O
displace	O
warfarin	B-O
from	O
plasma	O
protein	O
;	O
a	O
reduction	O
in	O
the	O
usual	O
anticoagulant	O
dosage	O
may	O
be	O
required	O
in	O
patients	O
receiving	O
both	O
drugs	O
.	O

Lithium	B-O
:	O
Metronidazole	B
has	O
been	O
reported	O
to	O
elevate	O
serum	O
lithium	B-O
levels	O
.	O

Phenytoin	B-O
,	O
Fosphenytoin	B-O
:	O
Concomitant	O
administration	O
of	O
oral	O
metronidazole	B
and	O
intravenous	O
phenytoin	B-O
was	O
reported	O
to	O
result	O
in	O
prolongation	O
of	O
the	O
half-life	O
and	O
reduction	O
in	O
the	O
clearance	O
of	O
phenytoin	B-O
.	O

Cyclosporine	B-O
,	O
Tacrolimus	B-O
:	O
There	O
are	O
several	O
case	O
reports	O
suggesting	O
that	O
metronidazole	B
has	O
the	O
potential	O
to	O
increase	O
the	O
levels	O
of	O
cyclosporine	B-O
and	O
tacrolimus	B-O
.	O

Fluorouracil	B-O
:	O
Metronidazole	B
was	O
shown	O
to	O
decrease	O
the	O
clearance	O
of	O
fluorouracil	B-O
,	O
resulting	O
in	O
an	O
increase	O
in	O
side-effects	O
without	O
an	O
increase	O
in	O
therapeutic	O
benefits	O
.	O

CYP3A4	B
Inducers	I
and	O
Inhibitors	O
:	O
Simultaneous	O
administration	O
of	O
tinidazole	B-O
with	O
drugs	B
that	I
induce	I
liver	I
microsomal	I
enzymes	I
,	O
i	O
.e	O
.	O
,	O
CYP3A4	B
inducers	I
such	O
as	O
phenobarbital	B
,	O
rifampin	B
,	O
phenytoin	B
,	O
and	O
fosphenytoin	B
(	O
a	O
pro-drug	O
of	O
phenytoin	B
)	O
,	O
may	O
accelerate	O
the	O
elimination	O
of	O
tinidazole	B-O
,	O
decreasing	O
the	O
plasma	O
level	O
of	O
tinidazole	B-O
.	O

Simultaneous	O
administration	O
of	O
drugs	B
that	I
inhibit	I
the	I
activity	I
of	I
liver	I
microsomal	I
enzymes	I
,	O
i	O
.e	O
.	O
,	O
CYP3A4	B
inhibitors	I
such	O
as	O
cimetidine	B
and	O
ketoconazole	B
,	O
may	O
prolong	O
the	O
half-life	O
and	O
decrease	O
the	O
plasma	O
clearance	O
of	O
tinidazole	B-O
,	O
increasing	O
the	O
plasma	O
concentrations	O
of	O
tinidazole	B-O
.	O

Cholestyramine	B
:	O
Cholestyramine	B
was	O
shown	O
to	O
decrease	O
the	O
oral	O
bioavailability	O
of	O
metronidazole	B-O
by	O
21	O
%	O
.	O

Administration	O
of	O
Tindamax	B-O
tablets	O
with	O
food	B
resulted	O
in	O
a	O
delay	O
in	O
T	O
max	O
of	O
approximately	O
2	O
hours	O
and	O
a	O
decline	O
in	O
C	O
max	O
of	O
approximately	O
10	O
%	O
,	O
compared	O
to	O
fasted	O
conditions	O
.	O

In	O
an	O
interaction	O
study	O
in	O
healthy	O
volunteers	O
,	O
entacapone	B
did	O
not	O
significantly	O
change	O
the	O
plasma	O
levels	O
of	O
S-warfarin	O
,	O
while	O
the	O
AUC	O
for	O
R-warfarin	B-O
increased	O
on	O
average	O
by	O
18	O
%	O
[CI90	O
11	O
%	O
to	O
26	O
%	O
]	O
,	O
and	O
the	O
international	O
normalized	O
ratio	O
(	O
INR	O
)	O
values	O
increased	O
on	O
average	O
by	O
13	O
%	O
[CI90	O
6	O
%	O
to	O
19	O
%	O
]	O
.	O

When	O
entacapone	B
is	O
given	O
in	O
conjunction	O
with	O
levodopa	B-O
and	O
an	O
aromatic	B
amino	I
acid	I
decarboxylase	I
inhibitor	I
,	O
such	O
as	O
carbidopa	B
,	O
plasma	O
levels	O
of	O
levodopa	B-O
are	O
greater	O
and	O
more	O
sustained	O
than	O
after	O
administration	O
of	O
levodopa	B-O
and	O
an	O
aromatic	B
amino	I
acid	I
decarboxylase	I
inhibitor	I
alone	O
.	O

When	O
200	O
mg	O
entacapone	B
is	O
administered	O
together	O
with	O
levodopa	B-O
and	O
carbidopa	B
,	O
it	O
increases	O
the	O
area	O
under	O
the	O
curve	O
(	O
AUC)	O
of	O
levodopa	B-O
by	O
approximately	O
35	O
%	O
,	O
and	O
the	O
elimination	O
half-life	O
of	O
levodopa	B-O
is	O
prolonged	O
from	O
1.3	O
hours	O
to	O
2.4	O
hours	O
.	O

When	O
colesevelam	B
is	O
coadministered	O
with	O
glipizide	B-O
ER	O
,	O
maximum	O
plasma	O
concentration	O
and	O
total	O
exposure	O
to	O
glipizide	B-O
is	O
reduced	O
.	O

The	O
mean	O
percentage	O
increase	O
in	O
the	O
GLUCOTROL	B-O
AUC	O
after	O
fluconazole	B
administration	O
was	O
56.9	O
%	O
(	O
range	O
:	O
35	O
to	O
81	O
)	O
.	O

In	O
studies	O
assessing	O
the	O
effect	O
of	O
colesevelam	B
on	O
the	O
pharmacokinetics	O
of	O
glipizide	B-O
ER	O
in	O
healthy	O
volunteers	O
,	O
reductions	O
in	O
glipizide	B-O
AUC0-Infinity	O
and	O
Cmax	O
of	O
12	O
%	O
and	O
13	O
%	O
,	O
respectively	O
were	O
observed	O
when	O
colesevelam	B
was	O
coadministered	O
with	O
glipizide	B-O
ER	O
.	O

Therefore	O
,	O
GLUCOTROL	B-O
should	O
be	O
administered	O
at	O
least	O
4	O
hours	O
prior	O
to	O
colesevelam	B
to	O
ensure	O
that	O
colesevelam	B
does	O
not	O
reduce	O
the	O
absorption	O
of	O
glipizide	B-O
.	O

Concurrent	O
administration	O
of	O
lorazepam	B-O
with	O
valproate	B
results	O
in	O
increased	O
plasma	O
concentrations	O
and	O
reduced	O
clearance	O
of	O
lorazepam	B-O
.	O

Concurrent	O
administration	O
of	O
lorazepam	B-O
with	O
probenecid	B
may	O
result	O
in	O
a	O
more	O
rapid	O
onset	O
or	O
prolonged	O
effect	O
of	O
lorazepam	B-O
due	O
to	O
increased	O
half-life	O
and	O
decreased	O
total	O
clearance	O
.	O

Effect	O
of	O
leucovorin	B
products	O
on	O
fluorouracil	B-O
:	O
Leucovorin	B
products	O
increase	O
the	O
toxicity	O
of	O
fluorouracil	B-O
.	O

Leucovorin	B
products	O
increase	O
the	O
toxicities	O
of	O
fluorouracil	B-O
.	O

Coadministration	O
of	O
ACTOS	B-O
and	O
gemfibrozil	B
,	O
a	O
strong	O
CYP2C8	O
inhibitor	O
,	O
increases	O
pioglitazone	B-O
exposure	O
approximately	O
3-fold	O
.	O

Strong	O
CYP2C8	B
inhibitors	I
(	O
e	O
.g.	O
,	O
gemfibrozil	B
)	O
increase	O
pioglitazone	B-O
concentrations	O
.	O

CYP2C8	B
inducers	I
(	O
e	O
.g.	O
,	O
rifampin	B
)	O
may	O
decrease	O
pioglitazone	B-O
concentrations	O
.	O

Topiramate	B
may	O
decrease	O
pioglitazone	B-O
concentrations	O
.	O

An	O
inhibitor	B
of	I
CYP2C8	I
(	O
e	O
.g.	O
,	O
gemfibrozil	B
)	O
significantly	O
increases	O
the	O
exposure	O
(area	O
under	O
the	O
serum	O
concentration-time	O
curve	O
or	O
AUC)	O
and	O
half-life	O
(	O
t1/2	O
)	O
of	O
pioglitazone	B-O
.	O

An	O
inducer	B
of	I
CYP2C8	I
(	O
e	O
.g.	O
,	O
rifampin	B
)	O
may	O
significantly	O
decrease	O
the	O
exposure	O
(	O
AUC)	O
of	O
pioglitazone	B-O
.	O

A	O
decrease	O
in	O
the	O
exposure	O
of	O
pioglitazone	B-O
and	I-O
its	I-O
active	I-O
metabolites	I-O
were	O
noted	O
with	O
concomitant	O
administration	O
of	O
pioglitazone	O
and	O
topiramate	B
.	O

In	O
an	O
in	O
vitro	O
study	O
in	O
human	O
liver	O
microsomes	O
,	O
inhibition	O
of	O
CYP2A6	O
hydroxylation	O
of	O
coumarin	B-O
by	O
fondaparinux	B
(	O
200	O
micromolar	O
i	O
.e	O
.	O
,	O
350	O
mg/L	O
)	O
was	O
17	O
to	O
28	O
%	O
.	O

Effects	O
of	O
NUVIGIL	B
on	O
CYP3A4/5	O
Substrates	O
The	O
clearance	O
of	O
drugs	B-O
that	I-O
are	I-O
substrates	I-O
for	I-O
CYP3A4/5	I-O
(	O
e	O
.g.	O
,	O
steroidal	B-O
contraceptives	I-O
,	O
cyclosporine	B-O
,	O
midazolam	B-O
,	O
and	O
triazolam	B-O
)	O
may	O
be	O
increased	O
by	O
NUVIGIL	B
via	O
induction	O
of	O
metabolic	O
enzymes	O
,	O
which	O
results	O
in	O
lower	O
systemic	O
exposure	O
.	O

Blood	O
levels	O
of	O
cyclosporine	B-O
may	O
be	O
reduced	O
when	O
used	O
with	I
NUVIGIL.	B

Effects	O
of	O
NUVIGIL	B
on	O
CYP2C19	O
Substrates	O
Elimination	O
of	O
drugs	B-O
that	I-O
are	I-O
substrates	I-O
for	I-O
CYP2C19	I-O
(	O
e	O
.g.	O
,	O
phenytoin	B-O
,	O
diazepam	B-O
,	O
propranolol	B-O
,	O
omeprazole	B-O
,	O
and	O
clomipramine	B-O
)	O
may	O
be	O
prolonged	O
by	O
NUVIGIL	B
via	O
inhibition	O
of	O
metabolic	O
enzymes	O
,	O
with	O
resultant	O
higher	O
systemic	O
exposure	O
.	O

Food	B
effect	O
on	O
the	O
overall	O
bioavailability	O
of	O
NUVIGIL	B-O
is	O
considered	O
minimal	O
;	O
however	O
,	O
time	O
to	O
reach	O
peak	O
concentration	O
(	O
tmax	O
)	O
may	O
be	O
delayed	O
by	O
approximately	O
2-4	O
hours	O
in	O
the	O
fed	O
state	O
.	O

Since	O
the	O
delay	O
in	O
tmax	O
is	O
also	O
associated	O
with	O
elevated	O
plasma	O
concentrations	O
later	O
in	O
time	O
,	O
food	B
can	O
potentially	O
affect	O
the	O
onset	O
and	O
time	O
course	O
of	O
pharmacologic	O
action	O
for	I-O
NUVIGIL.	B-O

In	O
a	O
clinical	O
study	O
,	O
concomitant	O
administration	O
of	O
NUVIGIL	B
250	O
mg	O
resulted	O
in	O
a	O
reduction	O
in	O
systemic	O
exposure	O
to	O
midazolam	B-O
by	O
32	O
%	O
after	O
a	O
single	O
oral	O
dose	O
(	O
5	O
mg	O
)	O
and	O
17	O
%	O
after	O
a	O
single	O
intravenous	O
dose	O
(	O
2	O
mg	O
)	O
.	O

Therefore	O
,	O
the	O
blood	O
levels	O
and	O
effectiveness	O
of	O
drugs	B-O
that	I-O
are	I-O
substrates	I-O
for	I-O
CYP3A	I-O
enzymes	I-O
(	O
e	O
.g.	O
,	O
steroidal	B-O
contraceptives	I-O
,	O
cyclosporine	B-O
,	O
midazolam	B-O
,	O
and	O
triazolam	B-O
)	O
may	O
be	O
reduced	O
after	O
initiation	O
of	O
concomitant	O
treatment	O
with	I
NUVIGIL.In	B
a	O
separate	O
clinical	O
study	O
,	O
concomitant	O
administration	O
of	O
NUVIGIL	B
250	O
mg	O
with	O
quetiapine	B-O
(	O
300	O
mg	O
to	O
600	O
mg	O
daily	O
doses	O
)	O
resulted	O
in	O
a	O
reduction	O
in	O
the	O
mean	O
systemic	O
exposure	O
of	O
quetiapine	B-O
by	O
approximately	O
29	O
%	O
.	O

In	O
a	O
clinical	O
study	O
,	O
concomitant	O
administration	O
of	O
NUVIGIL	B
400	O
mg	O
resulted	O
in	O
a	O
40	O
%	O
increase	O
in	O
exposure	O
to	O
omeprazole	B-O
after	O
a	O
single	O
oral	O
dose	O
(	O
40	O
mg	O
)	O
,	O
as	O
a	O
result	O
of	O
moderate	O
inhibition	O
of	O
CYP2C19	O
activity	O
.	O

Interactions	O
with	O
CNS	O
Active	O
Drugs	O
Concomitant	O
administration	O
of	O
NUVIGIL	B
with	O
quetiapine	B-O
reduced	O
the	O
systemic	O
exposure	O
of	O
quetiapine	B-O
.Data	O
specific	O
to	O
NUVIGIL	B
drug-drug	O
interaction	O
potential	O
with	O
other	O
CNS	O
active	O
drugs	O
are	O
not	O
available	O
.	O

Anticoagulants	O
Phenobarbital	B
lowers	O
the	O
plasma	O
levels	O
of	O
dicumarol	B-O
and	O
causes	O
a	O
decrease	O
in	O
anticoagulant	O
activity	O
as	O
measured	O
by	O
the	O
prothrombin	O
time	O
.	O

Barbiturates	B
can	O
induce	O
hepatic	O
microsomal	O
enzymes	O
,	O
resulting	O
in	O
increased	O
metabolism	O
and	O
decreased	O
anticoagulant	O
response	O
of	O
oral	B-O
anticoagulants	I-O
(eg	O
,	O
warfarin	B-O
,	O
acenocoumarol	B-O
,	O
dicumarol	B-O
,	O
and	O
phenprocoumon	B-O
)	O
.	O

Corticosteroids	O
Barbiturates	B
appear	O
to	O
enhance	O
the	O
metabolism	O
of	O
exogenous	B-O
corticosteroids	I-O
,	O
probably	O
through	O
the	O
induction	O
of	O
hepatic	O
microsomal	O
enzymes	O
.	O

Griseofulvin	B-O
Phenobarbital	B
appears	O
to	O
interfere	O
with	O
the	O
absorption	O
of	O
orally	O
administered	O
griseofulvin	B-O
,	O
thus	O
decreasing	O
its	O
blood	O
level	O
.	O

Doxycycline	B-O
Phenobarbital	B
has	O
been	O
shown	O
to	O
shorten	O
the	O
half-life	O
of	O
doxycycline	B-O
for	O
as	O
long	O
as	O
2	O
weeks	O
after	O
barbiturate	O
therapy	O
is	O
discontinued.This	O
mechanism	O
is	O
probably	O
through	O
the	O
induction	O
of	O
hepatic	O
microsomal	O
enzymes	O
that	O
metabolize	O
the	O
antibiotic	O
.	O

Sodium	B
valproate	I
and	O
valproic	B
acid	I
increase	O
the	O
secobarbital	B-O
sodium	I-O
serum	O
levels	O
;	O
therefore	O
,	O
secobarbital	B-O
sodium	I-O
blood	O
levels	O
should	O
be	O
monitored	O
closely	O
and	O
appropriate	O
dosage	O
adjustments	O
made	O
as	O
clinically	O
indicated	O
.	O

Monoamine	B
Oxidase	I
Inhibitors	I
(	O
MAOIs	O
)	O
MAOIs	O
prolong	O
the	O
effects	O
of	O
barbiturates	B-O
,	O
probably	O
because	O
metabolism	O
of	O
the	O
barbiturate	O
is	O
inhibited	O
.	O

Estradiol	B-O
,	O
Estrone	O
,	O
Progesterone	O
,	O
and	O
Other	O
Steroidal	O
Hormones	O
Pretreatment	O
with	O
or	O
concurrent	O
administration	O
of	O
phenobarbital	B
may	O
decrease	O
the	O
effect	O
of	O
estradiol	B-O
by	O
increasing	O
its	O
metabolism	O
.	O

Hepatic	B
enzyme-inducing	I
drugs	I
(	O
e	O
.g.	O
,	O
phenytoin	B
,	O
carbamazepine	B
,	O
phenobarbital	B
,	O
primidone	B
,	O
rifampin	B
)	O
can	O
increase	O
valproate	B-O
clearance	O
,	O
while	O
enzyme	B
inhibitors	I
(	O
e	O
.g.	O
,	O
felbamate	B
)	O
can	O
decrease	O
valproate	B-O
clearance	O
.	O

Therefore	O
increased	O
monitoring	O
of	O
valproate	B
and	O
concomitant	O
drug	O
concentrations	O
and	O
dosage	O
adjustment	O
are	O
indicated	O
whenever	O
enzyme-inducing	O
or	O
inhibiting	O
drugs	O
are	O
introduced	O
or	O
withdrawn	O
(	O
7.1	O
)	O
Aspirin	O
,	O
carbapenem	O
antibiotics	O
,	O
estrogen-containing	O
hormonal	O
contraceptives	O
:	O
Monitoring	O
of	O
valproate	B
concentrations	O
is	O
recommended	O
(	O
7.1	O
)	O
Co-administration	O
of	O
valproate	B
can	O
affect	O
the	O
pharmacokinetics	O
of	O
other	O
drugs	O
(	O
e	O
.g	O
.	O
diazepam	B-O
,	O
ethosuximide	B-O
,	O
lamotrigine	B-O
,	O
phenytoin	B-O
)	O
by	O
inhibiting	O
their	O
metabolism	O
or	O
protein	O
binding	O
displacement	O
(	O
7.2	O
)	O
Patients	O
stabilized	O
on	O
rufinamide	O
should	O
begin	O
valproate	B
therapy	O
at	O
a	O
low	O
dose	O
,	O
and	O
titrate	O
to	O
clinically	O
effective	O
dose	O
(	O
7.2	O
)	O
Dosage	O
adjustment	O
of	O
amitriptyline/nortriptyline	O
,	O
propofol	O
,	O
warfarin	O
,	O
and	O
zidovudine	O
may	O
be	O
necessary	O
if	O
used	O
concomitantly	O
with	O
Depacon	O
(	O
7.2	O
)	O
Topiramate	O
:	O
Hyperammonemia	O
and	O
encephalopathy	O
(	O
5.9	O
,	O
7.3	O
)	O
Drugs	O
that	O
affect	O
the	O
level	O
of	O
expression	O
of	O
hepatic	O
enzymes	O
,	O
particularly	O
those	O
that	O
elevate	O
levels	O
of	O
glucuronosyltransferases	O
(	O
such	O
as	O
ritonavir	O
)	O
,	O
may	O
increase	O
the	O
clearance	O
of	O
valproate	B
.	O

For	O
example	O
,	O
phenytoin	B
,	O
carbamazepine	B
,	O
and	O
phenobarbital	B
(	O
or	O
primidone	B
)	O
can	O
double	O
the	O
clearance	O
of	O
valproate	B-O
.	O

Drugs	O
for	O
which	O
a	O
potentially	O
important	O
interaction	O
has	O
been	O
observed	O
Aspirin	B
A	O
study	O
involving	O
the	O
co-administration	O
of	O
aspirin	B
at	O
antipyretic	O
doses	O
(	O
11	O
to	O
16	O
mg/kg	O
)	O
with	O
valproate	B-O
to	O
pediatric	O
patients	O
(	O
n	O
=	O
6	O
)	O
revealed	O
a	O
decrease	O
in	O
protein	O
binding	O
and	O
an	O
inhibition	O
of	O
metabolism	O
of	O
valproate	B-O
.	O

Valproate	B-O
free	O
fraction	O
was	O
increased	O
4-fold	O
in	O
the	O
presence	O
of	O
aspirin	B
compared	O
to	O
valproate	B-O
alone	O
.	O

Carbapenem	B
Antibiotics	I
A	O
clinically	O
significant	O
reduction	O
in	O
serum	O
valproic	B-O
acid	I-O
concentration	O
has	O
been	O
reported	O
in	O
patients	O
receiving	O
carbapenem	B
antibiotics	I
(	O
for	O
example	O
,	O
ertapenem	B
,	O
imipenem	B
,	O
meropenem	B
this	O
is	O
not	O
a	O
complete	O
list	O
)	O
and	O
may	O
result	O
in	O
loss	O
of	O
seizure	O
control	O
.	O

Estrogen-Containing	B
Hormonal	I
Contraceptives	I
Estrogen-containing	B
hormonal	I
contraceptives	I
may	O
increase	O
the	O
clearance	O
of	O
valproate	B-O
,	O
which	O
may	O
result	O
in	O
decreased	O
concentration	O
of	O
valproate	B-O
and	O
potentially	O
increased	O
seizure	O
frequency	O
.	O

Felbamate	B
A	O
study	O
involving	O
the	O
co-administration	O
of	O
1,200	O
mg/day	O
of	O
felbamate	B
with	O
valproate	B-O
to	O
patients	O
with	O
epilepsy	O
(	O
n	O
=	O
10	O
)	O
revealed	O
an	O
increase	O
in	O
mean	O
valproate	B-O
peak	O
concentration	O
by	O
35	O
%	O
(	O
from	O
86	O
to	O
115	O
mcg/mL	O
)	O
compared	O
to	O
valproate	B-O
alone	O
.	O

Increasing	O
the	O
felbamate	B
dose	O
to	O
2,400	O
mg/day	O
increased	O
the	O
mean	O
valproate	B-O
peak	O
concentration	O
to	O
133	O
mcg/mL	O
(	O
another	O
16	O
%	O
increase	O
)	O
.	O

Rifampin	B
A	O
study	O
involving	O
the	O
administration	O
of	O
a	O
single	O
dose	O
of	O
valproate	B-O
(	O
7	O
mg/kg	O
)	O
36	O
hours	O
after	O
5	O
nights	O
of	O
daily	O
dosing	O
with	O
rifampin	B
(	O
600	O
mg	O
)	O
revealed	O
a	O
40	O
%	O
increase	O
in	O
the	O
oral	O
clearance	O
of	O
valproate	B-O
.	O

Chlorpromazine	B
A	O
study	O
involving	O
the	O
administration	O
of	O
100	O
to	O
300	O
mg/day	O
of	O
chlorpromazine	B
to	O
schizophrenic	O
patients	O
already	O
receiving	O
valproate	B-O
(	O
200	O
mg	O
BID	O
)	O
revealed	O
a	O
15	O
%	O
increase	O
in	O
trough	O
plasma	O
levels	O
of	O
valproate	B-O
.	O

Drugs	O
for	O
which	O
a	O
potentially	O
important	O
valproate	B
interaction	O
has	O
been	O
observed	I-O
Amitriptyline/Nortriptyline	B-O
Administration	O
of	O
a	O
single	O
oral	O
50	O
mg	O
dose	O
of	O
amitriptyline	B-O
to	O
15	O
normal	O
volunteers	O
(	O
10	O
males	O
and	O
5	O
females	O
)	O
who	O
received	O
valproate	B
(	O
500	O
mg	O
BID	O
)	O
resulted	O
in	O
a	O
21	O
%	O
decrease	O
in	O
plasma	O
clearance	O
of	O
amitriptyline	B-O
and	O
a	O
34	O
%	O
decrease	O
in	O
the	O
net	O
clearance	O
of	O
nortriptyline	B-O
.	O

Rare	O
postmarketing	O
reports	O
of	O
concurrent	O
use	O
of	O
valproate	B
and	O
amitriptyline	B-O
resulting	O
in	O
an	O
increased	O
amitriptyline	B-O
level	O
have	O
been	O
received	O
.	O

Carbamazepine/carbamazepine-10,11-Epoxide	B-O
Serum	O
levels	O
of	O
carbamazepine	B-O
(	O
CBZ	O
)	O
decreased	O
17	O
%	O
while	O
that	O
of	I-O
carbamazepine-10,11-epoxide	B-O
(	O
CBZ-E)	O
increased	O
by	O
45	O
%	O
upon	O
co-administration	O
of	O
valproate	B
and	O
CBZ	O
to	O
epileptic	O
patients	O
.	O

Diazepam	B-O
Valproate	B
displaces	O
diazepam	B-O
from	O
its	O
plasma	O
albumin	O
binding	O
sites	O
and	O
inhibits	O
its	O
metabolism	O
.	O

Co-administration	O
of	O
valproate	B
(	O
1,500	O
mg	O
daily	O
)	O
increased	O
the	O
free	O
fraction	O
of	O
diazepam	B-O
(	O
10	O
mg	O
)	O
by	O
90	O
%	O
in	O
healthy	O
volunteers	O
(	O
n	O
=	O
6	O
)	O
.	O

Plasma	O
clearance	O
and	O
volume	O
of	O
distribution	O
for	O
free	O
diazepam	B-O
were	O
reduced	O
by	O
25	O
%	O
and	O
20	O
%	O
,	O
respectively	O
,	O
in	O
the	O
presence	O
of	O
valproate	B
.	O

Ethosuximide	B-O
Valproate	B
inhibits	O
the	O
metabolism	O
of	O
ethosuximide	B-O
.	O

Administration	O
of	O
a	O
single	O
ethosuximide	B-O
dose	O
of	O
500	O
mg	O
with	O
valproate	B
(	O
800	O
to	O
1,600	O
mg/day	O
)	O
to	O
healthy	O
volunteers	O
(	O
n	O
=	O
6	O
)	O
was	O
accompanied	O
by	O
a	O
25	O
%	O
increase	O
in	O
elimination	O
half-life	O
of	O
ethosuximide	B-O
and	O
a	O
15	O
%	O
decrease	O
in	O
its	O
total	O
clearance	O
as	O
compared	O
to	O
ethosuximide	B-O
alone	O
.	O

Lamotrigine	B-O
In	O
a	O
steady-state	O
study	O
involving	O
10	O
healthy	O
volunteers	O
,	O
the	O
elimination	O
half-life	O
of	O
lamotrigine	B-O
increased	O
from	O
26	O
to	O
70	O
hours	O
with	O
valproate	B
co-administration	O
(	O
a	O
165	O
%	O
increase	O
)	O
.	O

Phenobarbital	B-O
Valproate	B
was	O
found	O
to	O
inhibit	O
the	O
metabolism	O
of	O
phenobarbital	B-O
.	O

Co-administration	O
of	O
valproate	B
(	O
250	O
mg	O
BID	O
for	O
14	O
days	O
)	O
with	O
phenobarbital	B-O
to	O
normal	O
subjects	O
(	O
n	O
=	O
6	O
)	O
resulted	O
in	O
a	O
50	O
%	O
increase	O
in	O
half-life	O
and	O
a	O
30	O
%	O
decrease	O
in	O
plasma	O
clearance	O
of	O
phenobarbital	B-O
(	O
60	O
mg	O
single-dose	O
)	O
.	O

The	O
fraction	O
of	O
phenobarbital	B-O
dose	O
excreted	O
unchanged	O
increased	O
by	O
50	O
%	O
in	O
presence	O
of	O
valproate	B
.	O

Phenytoin	B-O
Valproate	B
displaces	O
phenytoin	B-O
from	O
its	O
plasma	O
albumin	O
binding	O
sites	O
and	O
inhibits	O
its	O
hepatic	O
metabolism	O
.	O

Co-administration	O
of	O
valproate	B
(	O
400	O
mg	O
TID	O
)	O
with	O
phenytoin	B-O
(	O
250	O
mg	O
)	O
in	O
normal	O
volunteers	O
(	O
n	O
=	O
7	O
)	O
was	O
associated	O
with	O
a	O
60	O
%	O
increase	O
in	O
the	O
free	O
fraction	O
of	O
phenytoin	B-O
.	O

Total	O
plasma	O
clearance	O
and	O
apparent	O
volume	O
of	O
distribution	O
of	O
phenytoin	B-O
increased	O
30	O
%	O
in	O
the	O
presence	O
of	O
valproate	B
.	O

Propofol	B-O
The	O
concomitant	O
use	O
of	O
valproate	B
and	O
propofol	B-O
may	O
lead	O
to	O
increased	O
blood	O
levels	O
of	O
propofol	B-O
.	O

Rufinamide	B-O
Based	O
on	O
a	O
population	O
pharmacokinetic	O
analysis	O
,	O
rufinamide	B-O
clearance	O
was	O
decreased	O
by	O
valproate	O
.	O

Rufinamide	B-O
concentrations	O
were	O
increased	O
by	O
<16	O
%	O
to	O
70	O
%	O
,	O
dependent	O
on	O
concentration	O
of	O
valproate	B
(	O
with	O
the	O
larger	O
increases	O
being	O
seen	O
in	O
pediatric	O
patients	O
at	O
high	O
doses	O
or	O
concentrations	O
of	O
valproate	B
)	O
.	O

Tolbutamide	B-O
From	O
in	O
vitro	O
experiments	O
,	O
the	O
unbound	O
fraction	O
of	O
tolbutamide	B-O
was	O
increased	O
from	O
20	O
%	O
to	O
50	O
%	O
when	O
added	O
to	O
plasma	O
samples	O
taken	O
from	O
patients	O
treated	O
with	O
valproate	B
.	O

Warfarin	B-O
In	O
an	O
in	O
vitro	O
study	O
,	O
valproate	B
increased	O
the	O
unbound	O
fraction	O
of	O
warfarin	B-O
by	O
up	O
to	O
32.6	O
%	O
.	O

Zidovudine	B-O
In	O
six	O
patients	O
who	O
were	O
seropositive	O
for	O
HIV	O
,	O
the	O
clearance	O
of	O
zidovudine	B-O
(	O
100	O
mg	O
q8h	O
)	O
was	O
decreased	O
by	O
38	O
%	O
after	O
administration	O
of	O
valproate	B
(	O
250	O
or	O
500	O
mg	O
q8h	O
)	O
;	O
the	O
half-life	O
of	O
zidovudine	B-O
was	O
unaffected	O
.	O

Lorazepam	B-O
Concomitant	O
administration	O
of	O
valproate	B
(	O
500	O
mg	O
BID	O
)	O
and	O
lorazepam	B-O
(	O
1	O
mg	O
BID	O
)	O
in	O
normal	O
male	O
volunteers	O
(	O
n	O
=	O
9	O
)	O
was	O
accompanied	O
by	O
a	O
17	O
%	O
decrease	O
in	O
the	O
plasma	O
clearance	O
of	O
lorazepam	B-O
.	O

Co-administration	O
of	O
valproate	B
(	O
500	O
mg	O
BID	O
)	O
and	O
olanzapine	B-O
(	O
5	O
mg	O
)	O
to	O
healthy	O
adults	O
(	O
n=10	O
)	O
caused	O
15	O
%	O
reduction	O
in	O
Cmax	O
and	O
35	O
%	O
reduction	O
in	O
AUC	O
of	O
olanzapine	B-O
.	O

Carbapenem	B
antibiotics	I
(	O
for	O
example	O
,	O
ertapenem	B
,	O
imipenem	B
,	O
meropenem	B
;	O
this	O
is	O
not	O
a	O
complete	O
list	O
)	O
may	O
reduce	O
serum	O
valproate	B-O
concentrations	O
to	O
subtherapeutic	O
levels	O
,	O
resulting	O
in	O
loss	O
of	O
seizure	O
control	O
.	O

Protein	O
binding	O
of	O
valproate	B-O
is	O
reduced	O
in	O
the	O
elderly	O
,	O
in	O
patients	O
with	O
chronic	O
hepatic	O
diseases	O
,	O
in	O
patients	O
with	O
renal	O
impairment	O
,	O
and	O
in	O
the	O
presence	O
of	O
other	O
drugs	O
(	O
e	O
.g.	O
,	O
aspirin	B
)	O
.	O

Conversely	O
,	O
valproate	B
may	O
displace	O
certain	O
protein-bound	B-O
drugs	I-O
(	O
e	O
.g.	O
,	O
phenytoin	B-O
,	O
carbamazepine	B-O
,	O
warfarin	B-O
,	O
and	O
tolbutamide	B-O
)	O
.	O

For	O
example	O
,	O
patients	O
taking	O
enzyme-inducing	B
antiepileptic	I
drugs	I
(	O
carbamazepine	B
,	O
phenytoin	B
,	O
and	O
phenobarbital	B
)	O
will	O
clear	O
valproate	B-O
more	O
rapidly	O
.	O

Dexamethasone	B
:	O
Steady-state	O
trough	O
concentrations	O
of	O
albendazole	B-O
sulfoxide	I-O
were	O
about	O
56	O
%	O
higher	O
when	O
dexamethasone	B
was	O
coadministered	O
with	O
each	O
dose	O
of	O
albendazole	O
.	O

Steady-state	O
trough	O
concentrations	O
of	O
albendazole	B-O
sulfoxide	I-O
were	O
about	O
56	O
%	O
higher	O
when	O
8	O
mg	O
dexamethasone	B
was	O
co-administered	O
with	O
each	O
dose	O
of	O
albendazole	O
(	O
15	O
mg/kg/day	O
)	O
in	O
8	O
neurocysticercosis	O
patients	O
.	O

In	O
the	O
fed	O
state	O
,	O
praziquantel	B
(	O
40	O
mg/kg	O
)	O
increased	O
mean	O
maximum	O
plasma	O
concentration	O
and	O
area	O
under	O
the	O
curve	O
of	O
albendazole	B-O
sulfoxide	I-O
by	O
about	O
50	O
%	O
in	O
healthy	O
subjects	O
(	O
n	O
=	O
10	O
)	O
compared	O
with	O
a	O
separate	O
group	O
of	O
subjects	O
(	O
n	O
=	O
6	O
)	O
given	O
albendazole	O
alone	O
.	O

Albendazole	B-O
sulfoxide	I-O
concentrations	O
in	O
bile	O
and	O
cystic	O
fluid	O
were	O
increased	O
(	O
about	O
2-fold	O
)	O
in	O
hydatid	O
cyst	O
patients	O
treated	O
with	O
cimetidine	B
(	O
10	O
mg/kg/day	O
)	O
(	O
n	O
=	O
7	O
)	O
compared	O
with	O
albendazole	O
(	O
20	O
mg/kg/day	O
)	O
alone	O
(	O
n	O
=	O
12	O
)	O
.	O

Oral	O
bioavailability	O
appears	O
to	O
be	O
enhanced	O
when	O
albendazole	O
is	O
coadministered	O
with	O
a	O
fatty	B
meal	I
(estimated	O
fat	O
content	O
40	O
grams	O
)	O
as	O
evidenced	O
by	O
higher	O
(up	O
to	O
5-fold	O
on	O
average	O
)	O
plasma	O
concentrations	O
of	O
albendazole	B-O
sulfoxide	I-O
as	O
compared	O
to	O
the	O
fasted	O
state	O
.	O

However	O
,	O
CONTRAVE	B-O
should	O
not	O
be	O
taken	O
with	O
a	O
high-fat	B
meal	I
because	O
of	O
a	O
resulting	O
significant	O
increase	O
in	O
bupropion	B-O
and	O
naltrexone	B-O
systemic	O
exposure	O
.	O

Drugs	O
Metabolized	O
by	O
CYP2D6	O
:	O
Bupropion	B
inhibits	O
CYP2D6	O
and	O
can	O
increase	O
concentrations	O
of	O
:	O
antidepressants	B-O
,	O
(	O
e	O
.g.	O
,	O
selective	B-O
serotonin	I-O
reuptake	I-O
inhibitors	I-O
and	O
many	O
tricyclics	B-O
)	O
,	O
antipsychotics	B-O
(	O
e	O
.g.	O
,	O
haloperidol	B-O
,	O
risperidone	B-O
and	O
thioridazine	B-O
)	O
,	O
beta-blockers	B-O
(	O
e	O
.g.	O
,	O
metoprolol	B-O
)	O
and	O
Type	B-O
1C	I-O
antiarrhythmics	I-O
(	O
e	O
.g.	O
,	O
propafenone	B-O
and	O
flecainide	B-O
)	O
:	O
Consider	O
dose	O
reduction	O
when	O
using	O
with	I
CONTRAVE.	B

Concomitant	O
Treatment	O
with	O
CYP2B6	B
Inhibitors	I
(	O
e	O
.g.	O
,	O
ticlopidine	B
or	O
clopidogrel	B
)	O
can	O
increase	O
bupropion	B-O
exposure	O
.	O

CYP2B6	B
Inducers	I
(	O
e	O
.g.	O
,	O
ritonavir	B
,	O
lopinavir	B
,	O
efavirenz	B
,	O
carbamazepine	B
,	O
phenobarbital	B
,	O
and	O
phenytoin	B
)	O
may	O
reduce	O
efficacy	O
by	O
reducing	O
bupropion	B-O
exposure	O
,	O
avoid	O
concomitant	O
use	O
.	O

Studies	O
in	O
animals	O
demonstrate	O
that	O
the	O
acute	O
toxicity	O
of	O
bupropion	B-O
is	O
enhanced	O
by	O
the	O
MAOI	O
phenelzine	B
.	O

CONTRAVE	B
increased	O
metoprolol	B-O
AUC	O
and	O
Cmax	O
by	O
approximately	O
4-	O
and	O
2-fold	O
,	O
respectively	O
,	O
relative	O
to	O
metoprolol	B-O
alone	O
.	O

Inhibitors	O
of	O
CYP2B6	O
:	O
Ticlopidine	B
and	O
Clopidogrel	B
:	O
Concomitant	O
treatment	O
with	O
these	O
drugs	O
can	O
increase	O
bupropion	B-O
exposure	O
but	O
decrease	O
hydroxybupropion	B-O
exposure	O
.	O

Inducers	O
of	O
CYP2B6	O
:	O
Ritonavir	B
,	O
Lopinavir	B
,	O
and	O
Efavirenz	B
:	O
Concomitant	O
treatment	O
with	O
these	O
drugs	O
can	O
decrease	O
bupropion	B-O
and	O
hydroxybupropion	B-O
exposure	O
and	O
may	O
reduce	O
efficacy	O
.	O

The	O
systemic	O
concentrations	O
of	O
substrate	B-O
drugs	I-O
transported	I-O
by	I-O
OCT2	I-O
(	O
such	O
as	O
amantadine	B-O
,	O
amiloride	B-O
,	O
cimetidine	B-O
,	O
dopamine	B-O
,	O
famotidine	B-O
,	O
memantine	B-O
,	O
metformin	B-O
,	O
pindolol	B-O
,	O
procainamide	B-O
,	O
ranitidine	B-O
,	O
varenicline	B-O
,	O
oxaliplatin	B-O
)	O
are	O
likely	O
to	O
increase	O
as	O
a	O
result	O
of	O
reduced	O
renal	O
clearance	O
when	O
coadministered	O
with	I
CONTRAVE.	B

Food	O
Effect	O
on	O
Absorption	O
When	O
CONTRAVE	B-O
was	O
administered	O
with	O
a	O
high-fat	B
meal	I
,	O
the	O
AUC	O
and	O
Cmax	O
for	O
naltrexone	B-O
increased	O
2.1-fold	O
and	O
3.7-fold	O
,	O
respectively	O
,	O
and	O
the	O
AUC	O
and	O
Cmax	O
for	O
bupropion	B-O
increased	O
1.4-fold	O
and	O
1.8-fold	O
,	O
respectively	O
.	O

At	O
steady	O
state	O
,	O
the	O
food	B
effect	O
increased	O
AUC	O
and	O
Cmax	O
for	O
naltrexone	B-O
by	O
1.7-fold	O
and	O
1.9-fold	O
,	O
respectively	O
,	O
and	O
increased	O
AUC	O
and	O
Cmax	O
for	O
bupropion	B-O
by	O
1.1-fold	O
and	O
1.3-fold	O
,	O
respectively	O
.	O

Thus	O
,	O
CONTRAVE	B-O
should	O
not	O
be	O
taken	O
with	O
high-fat	B
meals	I
because	O
of	O
the	O
resulting	O
significant	O
increases	O
in	O
bupropion	B-O
and	O
naltrexone	B-O
systemic	O
exposure	O
.	O

In	O
vitro	O
studies	O
suggest	O
that	O
paroxetine	B
,	O
sertraline	B
,	O
norfluoxetine	B
,	O
fluvoxamine	B
,	O
and	O
nelfinavir	B
inhibit	O
the	O
hydroxylation	O
of	O
bupropion	B-O
.	O

While	O
not	O
systematically	O
studied	O
,	O
carbamazepine	B
,	O
phenobarbital	B
,	O
or	O
phenytoin	B
may	O
induce	O
the	O
metabolism	O
of	O
bupropion	B-O
.	O

Chlorpheniramine	B
may	O
inhibit	O
the	O
hepatic	O
metabolism	O
of	O
phenytoin	B-O
,	O
monitor	O
phenytoin	B-O
toxicity	O
.	O

Adverse	O
event	O
reports	O
in	O
the	O
literature	O
suggest	O
a	O
possible	O
drug	O
interaction	O
involving	O
increased	O
serum	O
phenytoin	B-O
levels	O
and	O
phenytoin	B-O
toxicity	O
when	O
chlorpheniramine	B
and	O
phenytoin	B-O
are	O
co-administered	O
.	O

The	O
exact	O
mechanism	O
for	O
this	O
interaction	O
is	O
not	O
known	O
,	O
however	O
it	O
is	O
believed	O
that	O
chlorpheniramine	B
may	O
inhibit	O
the	O
hepatic	O
metabolism	O
of	O
phenytoin	B-O
.	O

There	O
was	O
a	O
slight	O
increase	O
in	O
the	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
,	O
11	O
%	O
)	O
and	O
mean	O
peak	O
drug	O
concentration	O
(	O
Cmax	O
,	O
18	O
%	O
)	O
of	O
digoxin	B-O
with	O
the	O
coadministration	O
of	O
100	O
mg	O
sitagliptin	B
for	O
10	O
days	O
.	O

Cimetidine	B
:	O
Acyclovir	B-O
Cmax	O
and	O
AUC	O
following	O
a	O
single	O
dose	O
of	O
VALTREX	B-O
(	O
1	O
gram	O
)	O
increased	O
by	O
8	O
%	O
and	O
32	O
%	O
,	O
respectively	O
,	O
after	O
a	O
single	O
dose	O
of	O
cimetidine	B
(	O
800	O
mg	O
)	O
.	O

Cimetidine	B
Plus	O
Probenecid	B
:	O
Acyclovir	B-O
Cmax	O
and	O
AUC	O
following	O
a	O
single	O
dose	O
of	O
VALTREX	B-O
(	O
1	O
gram	O
)	O
increased	O
by	O
30	O
%	O
and	O
78	O
%	O
,	O
respectively	O
,	O
after	O
a	O
combination	O
of	O
cimetidine	B
and	O
probenecid	B
,	O
primarily	O
due	O
to	O
a	O
reduction	O
in	O
renal	O
clearance	O
of	O
acyclovir	B-O
.	O

Probenecid	B
:	O
Acyclovir	B-O
Cmax	O
and	O
AUC	O
following	O
a	O
single	O
dose	O
of	O
VALTREX	B-O
(	O
1	O
gram	O
)	O
increased	O
by	O
22	O
%	O
and	O
49	O
%	O
,	O
respectively	O
,	O
after	O
probenecid	B
(	O
1	O
gram	O
)	O
.	O

Administration	O
with	O
rifampin	B
or	O
rifabutin	B
is	O
known	O
to	O
reduce	O
atovaquone	B-O
concentrations	O
;	O
concomitant	O
use	O
with	O
MALARONE	B-O
is	O
not	O
recommended	O
.	O

Tetracycline	B
may	O
reduce	O
atovaquone	B-O
concentrations	O
;	O
parasitemia	O
should	O
be	O
closely	O
monitored	O
.	O

Concomitant	O
administration	O
of	O
rifampin	B
or	O
rifabutin	B
is	O
known	O
to	O
reduce	O
atovaquone	B-O
concentrations	O
.	O

Concomitant	O
treatment	O
with	O
tetracycline	B
has	O
been	O
associated	O
with	O
a	O
reduction	O
in	O
plasma	O
concentrations	O
of	O
atovaquone	B-O
.	O

While	O
antiemetics	O
may	O
be	O
indicated	O
for	O
patients	O
receiving	O
MALARONE	B-O
,	O
metoclopramide	B
may	O
reduce	O
the	O
bioavailability	O
of	O
atovaquone	B-O
and	O
should	O
be	O
used	O
only	O
if	O
other	O
antiemetics	O
are	O
not	O
available	O
.	O

Concomitant	O
administration	O
of	O
atovaquone	B
and	O
indinavir	B-O
did	O
not	O
result	O
in	O
any	O
change	O
in	O
the	O
steady-state	O
AUC	O
and	O
Cmax	O
of	O
indinavir	B-O
but	O
resulted	O
in	O
a	O
decrease	O
in	O
the	O
Ctrough	O
of	O
indinavir	B-O
.	O

Caution	O
should	O
be	O
exercised	O
when	O
prescribing	O
atovaquone	B
with	O
indinavir	B-O
due	O
to	O
the	O
decrease	O
in	O
trough	O
concentrations	O
of	O
indinavir	B-O
.	O

Dietary	B
fat	I
taken	O
with	O
atovaquone	B-O
increases	O
the	O
rate	O
and	O
extent	O
of	O
absorption	O
,	O
increasing	O
AUC	O
2	O
to	O
3	O
times	O
and	O
Cmax	O
5	O
times	O
over	O
fasting	O
.	O

Rifampin/Rifabutin	B
:	O
Concomitant	O
administration	O
of	O
rifampin	B
or	O
rifabutin	B
is	O
known	O
to	O
reduce	O
atovaquone	B-O
concentrations	O
by	O
approximately	O
50	O
%	O
and	O
34	O
%	O
,	O
respectively	O
.	O

Tetracycline	B
:	O
Concomitant	O
treatment	O
with	O
tetracycline	B
has	O
been	O
associated	O
with	O
approximately	O
a	O
40	O
%	O
reduction	O
in	O
plasma	O
concentrations	O
of	O
atovaquone	B-O
.	O

Metoclopramide	B
:	O
Concomitant	O
treatment	O
with	O
metoclopramide	B
has	O
been	O
associated	O
with	O
decreased	O
bioavailability	O
of	O
atovaquone	B-O
.	O

Indinavir	B-O
:	O
Concomitant	O
administration	O
of	O
atovaquone	B
(	O
750	O
mg	O
twice	O
daily	O
with	O
food	O
for	O
14	O
days	O
)	O
and	O
indinavir	B-O
(	O
800	O
mg	O
three	O
times	O
daily	O
without	O
food	O
for	O
14	O
days	O
)	O
did	O
not	O
result	O
in	O
any	O
change	O
in	O
the	O
steady-state	O
AUC	O
and	O
Cmax	O
of	O
indinavir	B-O
but	O
resulted	O
in	O
a	O
decrease	O
in	O
the	O
Ctrough	O
of	O
indinavir	B-O
(	O
23	O
%	O
decrease	O
[90	O
%	O
CI	O
=	O
8	O
%	O
,	O
35	O
%	O
]	O
)	O
.	O

Deferasirox	B
increases	O
the	O
exposure	O
of	O
repaglinide	B-O
.	O

Avoid	O
the	O
use	O
of	O
JADENU	B
with	O
theophylline	B-O
as	O
theophylline	B-O
levels	O
could	O
be	O
increased	O
.	O

Deferasirox	B
increases	O
exposure	O
of	O
busulfan	B-O
.	O

Deferasirox	B
inhibits	O
CYP2C8	O
resulting	O
in	O
an	O
increase	O
in	O
CYP2C8	B-O
substrate	I-O
(	O
e	O
.g.	O
,	O
repaglinide	B-O
and	O
paclitaxel	B-O
)	O
concentration	O
when	O
these	O
drugs	O
are	O
coadministered	O
.	O

Deferasirox	B
inhibits	O
CYP1A2	O
resulting	O
in	O
an	O
increase	O
in	O
CYP1A2	B-O
substrate	I-O
(	O
e	O
.g.	O
,	O
alosetron	B-O
,	O
caffeine	B-O
,	O
duloxetine	B-O
,	O
melatonin	B-O
,	O
ramelteon	B-O
,	O
tacrine	B-O
,	O
theophylline	B-O
,	O
tizanidine	B-O
)	O
concentration	O
when	O
these	O
drugs	O
are	O
coadministered	O
.	O

The	O
concomitant	O
use	O
of	O
JADENU	B-O
with	O
strong	O
UGT	B
inducers	I
(	O
e	O
.g.	O
,	O
rifampicin	B
,	O
phenytoin	B
,	O
phenobarbital	B
,	O
ritonavir	B
)	O
may	O
result	O
in	O
a	O
decrease	O
in	O
JADENU	B-O
efficacy	O
due	O
to	O
a	O
possible	O
decrease	O
in	O
deferasirox	B-O
concentration	O
.	O

Avoid	O
the	O
concomitant	O
use	O
of	O
bile	B
acid	I
sequestrants	I
(	O
e	O
.g.	O
,	O
cholestyramine	B
,	O
colesevelam	B
,	O
colestipol	B
)	O
with	O
JADENU	B-O
due	O
to	O
a	O
possible	O
decrease	O
in	O
deferasirox	B-O
concentration	O
.	O

Increased	O
exposure	O
of	O
busulfan	B-O
was	O
observed	O
with	O
concomitant	O
use	O
with	O
deferasirox	B
.	O

The	O
administration	O
of	O
JADENU	B-O
tablets	O
with	O
a	O
high-fat	B
meal	I
(	O
approximately	O
1000	O
calories	O
with	O
fat	O
content	O
greater	O
than	O
50	O
%	O
of	O
total	O
calories	O
)	O
,	O
increased	O
AUCinf	O
by	O
18	O
%	O
and	O
Cmax	O
by	O
29	O
%	O
compared	O
to	O
that	O
under	O
fasting	O
conditions	O
.	O

The	O
administration	O
of	O
JADENU	B-O
Sprinkle	O
granules	O
with	O
a	O
high-fat	B
meal	I
(	O
approximately	O
1000	O
calories	O
with	O
fat	O
content	O
greater	O
than	O
50	O
%	O
of	O
total	O
calories	O
)	O
increased	O
AUCinf	O
by	O
18	O
%	O
with	O
no	O
changes	O
in	O
Cmax	O
compared	O
to	O
that	O
under	O
fasting	O
conditions	O
.	O

Deconjugation	O
of	O
glucuronide	O
metabolites	O
in	O
the	O
intestine	O
and	O
subsequent	O
reabsorption	O
(	O
enterohepatic	O
recycling	O
)	O
was	O
confirmed	O
in	O
a	O
healthy	O
subjects	O
study	O
in	O
which	O
the	O
administration	O
of	O
cholestyramine	B
12	O
g	O
twice	O
daily	O
(	O
strongly	O
binds	O
to	O
deferasirox	B-O
and	O
its	O
conjugates	O
)	O
4	O
and	O
10	O
hours	O
after	O
a	O
single	O
dose	O
of	O
deferasirox	B-O
resulted	O
in	O
a	O
45	O
%	O
decrease	O
in	O
deferasirox	B-O
exposure	O
(	O
AUCinf	O
)	O
by	O
interfering	O
with	O
the	O
enterohepatic	O
recycling	O
of	O
deferasirox	B-O
.	O

Drug	O
Interactions	O
Midazolam	B-O
:	O
The	O
concomitant	O
administration	O
of	O
deferasirox	B
tablets	O
for	O
oral	O
suspension	O
and	O
CYP3A4	O
probe	O
substrate	O
midazolam	B-O
resulted	O
in	O
a	O
decrease	O
of	O
midazolam	B-O
Cmax	O
by	O
23	O
%	O
and	O
AUCinf	O
by	O
17	O
%	O
.	O

Repaglinide	B-O
:	O
The	O
concomitant	O
administration	O
of	O
deferasirox	B
tablets	O
for	O
oral	O
suspension	O
(	O
30	O
mg	O
per	O
kg/day	O
for	O
4	O
days	O
)	O
and	O
the	O
CYP2C8	O
probe	O
substrate	O
repaglinide	B-O
(	O
single	O
dose	O
of	O
0.5	O
mg	O
)	O
increased	O
repaglinide	B-O
AUCinf	O
to	O
2.3-fold	O
and	O
Cmax	O
of	O
1.6-fold	O
.	O

Theophylline	B-O
:	O
The	O
concomitant	O
administration	O
of	O
deferasirox	B
tablets	O
for	O
oral	O
suspension	O
(	O
repeated	O
dose	O
of	O
30	O
mg	O
per	O
kg/day	O
)	O
and	O
the	O
CYP1A2	O
substrate	O
theophylline	B-O
(	O
single	O
dose	O
of	O
120	O
mg	O
)	O
resulted	O
in	O
an	O
approximate	O
doubling	O
of	O
the	O
theophylline	B-O
AUCinf	O
and	O
elimination	O
half-life	O
.	O

Rifampicin	B
:	O
The	O
concomitant	O
administration	O
of	O
deferasirox	B-O
tablets	O
for	O
oral	O
suspension	O
(	O
single	O
dose	O
of	O
30	O
mg	O
per	O
kg	O
)	O
and	O
the	O
strong	O
uridine	O
diphosphate	O
glucuronosyltransferase	O
(	O
UGT	O
)	O
inducer	O
rifampicin	B
(	O
600	O
mg	O
per	O
day	O
for	O
9	O
days	O
)	O
decreased	O
deferasirox	B-O
AUCinf	O
by	O
44	O
%	O
.	O

Cholestyramine	B
:	O
The	O
concomitant	O
administration	O
of	O
cholestyramine	B
after	O
a	O
single	O
dose	O
of	O
deferasirox	B-O
tablets	O
for	O
oral	O
suspension	O
decreased	O
deferasirox	B-O
AUCinf	O
by	O
45	O
%	O
.	O

